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ABSTRACT
Title- -“The Study of the natural history of multiple sclerosis in the Indian 
perspective: Experience from a Tertiary care hospital” 
Department:  Neurology, Christian medical college, Vellore.
Name of the candidate   : Dr. Subhransu Sekhar Jena
Degree and Subject        : DM – Neurology
Name of the guide           : Dr. Mathew Alexander, DM (Neuro)
Introduction- Multiple sclerosis (MS) is an inflammatory demyelinating disease 
of the central nervous system, with a wide spectrum of clinical presentation, a 
disorder which starts as an inflammatory disorder and progresses to a degenerative 
phase with significant axonopathy. This stresses the importance of initiation of 
early DMDs. There is a lot of heterogeneity in the type of MS seen in the western 
and Eastern hemispheres, both in the clinical spectrum, topography of involvement 
and differences in natural history. However there is a paucity of reports about 
natural history of MS from India.
Aim/Objective- To study the spectrum, clinical, imaging, electrophysiological and 
CSF characteristics of Indian MS with respect to outcome and natural history..
Methodology- Retrospective analysis of patients diagnosed to have MS in the Dept. 
of Neurology at CMC, Vellore, during a period of 12 years (2000-2012). The 
Clinical data included antecedent events, clinical symptoms and signs, detailed 
imaging data with MRI, electrophysiological data including evoked potentials, CSF 
pattern, treatment details and follow up data for response to treatment were entered 
into a detailed proforma. Information was obtained from the outpatient case records, 
discharge summaries and follow up. We performed descriptive analyses using the 
Chi-square and Fisher`s exact tests for categorical variable and the student`s t test 
for continuous variable. Multiple binary logistic regressions were done for 
significance.
Results- 157patients with female preponderance were included in the study.114 
patients with follow up 6.16 yrs (±6.29) were analyzed for outcome analysis. The 
most common variety of MS diagnosed was relapsing remitting (RRMS) type 
(54.1%). Progressive form of MS (PP, SP) were having significant worse outcome 
(OR-3.51, 95%CI-2.228-7.98, p=0.004) comparing to relapsing MS after analyzing 
by multiple logistic regression. EDSS of patients at presentation and at final follow 
up after 6.16±6.29 years was 4.4±1.31 and 4.1±2.31 respectively. During the first 
presentation, incomplete recovery, polysymptomatic symptoms like motor and 
sphincter involvement and during the disease course, bowel, bladder, cerebellar 
and pyramidal affection predict worse outcome. The MRI of brain showing 
cerebellar lesion and cerebral atrophy has correlation with disability progression. 
CSF oligoclonal band was positive in 36.3%. CSF analysis and evoked potential 
did not predict about outcome. Treatment with Mycophenolate is having good 
outcome (O.R-0.284(C.I-0.11-0.683) p=0.0051. in univariate analysis.  The OSMS 
group had a better outcome with Mycophenolate when compared to NonOSMS 
group, suggesting that this probably represents the NMO spectrum. 
Conclusion- The present study highlights the regional and racial variations in the 
clinical, imaging and laboratory profile of multiple sclerosis.  There is a definite 
need for a good marker for disease activity to decide form of DMDs and predict 
response for treatment outcome.
. 
Total – 440 words excluding title and name.
1 
 
INTRODUCTION 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system, thought to result from immune response to myelin with variability in frequency and 
chronicity. The spectrum of disease course may include an acute isolated attack without 
recurrence, recurrent exacerabations, or a progressive phase. The impact of acute events is 
determined by the extent and severity of pathology. Accumulating long-term disability is 
believed to be determined by the balance between demyelination, remyelination, and axonal 
loss. Disease course, impact of individual events through out the course, and accumulating 
long-term disability collectively deﬁne disease severity and natural history. Current 
understanding of MS pathogenesis suggests that axonal damage starts early in MS
1
and that 
early intervention promises the beneﬁt of preventing long-term disability. Long-term beneﬁt 
with minimal toxicity is optimized by treating patients at the optimal point in their disease 
course.  
Variation in the prevalence of MS according to geographical location and the modification of 
clinical features by ethnic factors are well known. Contrary to the previous belief, that MS is 
rare in India, recent study suggested that the prevalence rate has increased consequent with 
the availability of MRI imaging, use of modern investigative facilities and increased 
awareness.
2  
Previous studies have suggested that Indian and Asian patients with MS behave somewhat 
differently from their western counterparts. They have greater optic nerve and spinal 
involvement. 
2–10
In India, there is an increased prevalence of recurrent acute transverse 
2 
 
myelitis, high incidence of optico-spinal involvement, severe involvement of spinal cord with 
greater functional disability and less frequent involvement of cerebellum is seen. However 
there is a paucity of reports about natural history of MS from India. 
Two Indian studies have narrated experience of beta interferon
11
 and Mitoxantrone
12
 
recently. Standard of care provided in our hospital is usually IV methylprednisolone for acute 
attacks and relapses Azathioprine (AZT) and of recently, Mycophenolate mofetil (MMF). 
The main limitation for the use of DMD like IFN or Glatiramer acetate (GA) has been for the 
reason of affordability and lack of Insurance coverage for the expenses. We have used 
interferon in the form of interferon beta-1a in selected patients. Pulse IV methylprednisolone 
was used in a few selected cases of RRMS, where there were frequent relapses while on 
AZT, and pulse Cyclophosphamide in some refractory cases.  Mitoxantrone has been given 
for a few patients with progressive MS.  On the basis of several, but somewhat conflicting, 
Class I and II studies, it is considered possible that azathioprine reduces the relapse rate in 
patients with MS (Type C recommendation).
13
The lack of formulation of IFN and GA, which 
could be efficacious and cost effective, is mostly for industry driven reasons. Hence, this 
study was undertaken to look at the clinical spectrum of disease and to look at the natural 
history of MS in a tertiary level hospital, where DMD like AZT, MMF, and 
Cyclophosphamide have been used. 
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AIMS AND OBJECTIVES 
 
Objectives: 
To study the clinical profile, imaging, electrophysiological and CSF characteristics with 
special reference to outcome in a cohort of patients diagnosed to have Multiple Sclerosis in 
the Department of Neurology at CMC, Vellore, during a period of 12 years (2000-2012). 
Outcome  
Development of Relapse /disability progression (EDSS) of Multiple Sclerosis as per 
established Criteriae. 
 Sub Aims 
 To look at the spectrum of clinical presentation of the disease. 
 To look at the utility of various electrophysiological tests including multimode 
evoked potentials in detecting subclinical neuroaxis sites. 
 To look for predictors for relapse/recurrence/progressive forms of Multiple 
sclerosis. 
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REVIEW OF LITERATURE 
HISTORY 
The first case of MS, in history dates back to 1433, when a Dutch saint named Lidwina was 
diagnosed retrospectively. In 1868, Jean-Martin Charcot, a Professor of Neurology at the 
University of Paris, who has been called "the father of neurology‖, has described the disease 
as sclerose en plaques.Beta-interferon 1b (Betaseron) was approved as the first drug to alter 
the course of MS in 1993. The face of MS has changed considerably over the past 10 years. 
Several conceptual shifts have occurred in the past decade that have resulted in improved 
understanding of disease processes that in turn have ultimately advanced patient care. 
PATHOGENESIS — MS is a heterogeneous disorder with variable clinical and pathologic 
features reflecting different pathways to tissue injury.
 14
Inflammation, demyelination, and 
axon degeneration are major pathologic mechanisms.
15
The most widely accepted theory is 
that MS begins as an inflammatory autoimmune disorder mediated by auto reactive 
lymphocytes.
14,16 
 Later, the disease is dominated by microglial activation and chronic neuro 
degeneration.
15
 
 
Myelin reactive T cells are found in MS plaques and in the CSF and 
peripheral circulation of patients with MS.
 17,18
T helper 17-type immune activation, mediated 
in part by interleukin 23 expression, is associated with active MS lesions.
19–21   
The risk of 
developing MS is associated with certain class I and class II alleles of the major 
histocompatibility complex (MHC)
22–27
, loci that are involved in T-cell activation and 
regulation. In addition, mounting evidence suggests that the risk of MS is associated with 
multiple non-MHC susceptibility genes of modest effect (eg, CD6, CLEC16A, IL2RA, IL7R, 
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IRF8, and TNFRSF1A)
 23,25,26
.Reduction in MS disease activity has been demonstrated with 
immunomodulatory drugs that reduce the Th1 immune response (ie, interferon beta), increase 
the Th2 and Th3 responses (ie, Glatiramer acetate), or block T-cell movement from the blood 
into the central nervous system (i.e., Natalizumab).An animal model of MS (experimental 
allergic encephalomyelitis or EAE) can be induced by myelin antigens
 28
, including myelin 
basic protein (MBP), proteolipid protein (PLP), myelin associated glycoprotein (MAG), and 
myelin oligodendrocyte glycoprotein (MOG)
 29
.In addition to loss of myelin and 
oligodendrocytes, axonal injury is a prominent pathologic feature of the multiple sclerosis 
plaque.
 1,30–32
Disease progression involves a degenerative phase of cerebral atrophy and 
axonal loss that is not clearly related to immune mechanisms or inflammation. 
EPIDEMIOLOGY AND RISK FACTORS 
A systematic review of 28 epidemiologic studies found that, from 1955 to 2000, the 
estimated female to male ratio of MS incidence increased from 1.4 to 2.3
 33
. The median and 
mean ages of MS onset are 23.5 and 30 years of age, respectively. The peak age of onset is 
about five years earlier for women than for men. RRMS tends to have an earlier onset, 
averaging 25 to 29 years; this may convert to SPMS at a mean age of 40 to 44 years. PPMS 
have a mean age of onset of 35 to 39 years. The incidence and prevalence of MS varies 
geographically
 34,35
. There is also a widely held belief of an association between latitude and 
MS, with the risk of MS increasing from south to north.
33 
One proposed explanation for the 
possible association of MS with latitude is that exposure to sunlight may be protective, either 
because of an effect of ultraviolet radiation or of vitamin D.
 36
A number of studies has 
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suggested an association between smoking and MS.
37    
The month of birth has been 
implicated as a possible risk factor for MS.
38 
CLINICAL FEATURES 
The disease has a highly variable pace and many atypical forms. Features highly suggestive 
of MS are relapses and remissions, onset between ages 15 and 50, optic neuritis, Lhermitte's 
sign, Internuclear ophthalmoplegia, fatigue, Uhthoff's phenomenon. Presenting symptoms 
and signs may be either monofocal (consistent with a single lesion) or multifocal (consistent 
with more than one lesion). Affective disorder occurs in up to two-thirds of patients with MS, 
and depression is the most common manifestation.  Thirty four to 65 percent of patients have 
cognitive impairment on the basis of neuropsychological testing, and it may be a common 
event at the onset of MS. The most frequent abnormalities are with abstract 
conceptualization, recent memory, attention, and speed of information processing. Epilepsy 
is more common in patients with MS than in the general population, occurring in 2 to 3 
percent of patients. Seizures may be either tonic-clonic in nature or partial complex in 
semilogy.  
Analysis of prospectively collected data from a cohort of 195 patients suggests that 
symptomatic demyelinating events in early RRMS have a tendency to recur in the same 
location (eg, spinal cord, optic nerve, and brainstem).
39 
Summaries of many studies provide an average figure of 0.4 to 0.6 relapses per year. 
Relapses tend to be more frequent during the first years of the disease and wane in later 
years. 
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In a single centre study that analyzed data from 2587 relapses occurring in 1078 patients 
during an average follow-up of 7.4 years, relapses causing permanent disability were rare.
40 
DISEASE PATTERN — The pattern and course of MS is categorized as follows41: 
1. Relapsing remitting (RRMS) - 85 to 90% of MS cases at onset.  
2. Secondary progressive (SPMS) - Ultimately develops in most patients with 
RRMS and causes the greatest amount of neurological disability. 
3. Primary progressive (PPMS) – 10% of cases at disease onset.42 
4. Progressive relapsing (PRMS). 
A clinic-based study of 1100 patients found that 66 % had RRMS disease at onset, 15 
%PRMS, and 19 % PPMS.
43
 
Clinical course can evolve from relapsing to SPMS; 85 percent of patients begin with a 
relapsing course, but the proportion remaining as relapsing falls steadily, so that only one-
half are still relapsing by nine years from onset. Course of MS with onset after the age of 40 
years is progressive in over 60 % of patients.
43 
Clinically isolated syndromes — clinically isolated syndromes are single, monosymptomatic 
attacks compatible with MS (eg, optic neuritis) that can create a diagnostic, and therefore 
therapeutic, dilemma.  
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Tumefactive multiple sclerosis — An acute tumor-like MS variant has been described in 
which some patients with demyelinating disease present with large (>2 cm) acute lesions, 
often associated with edema or ring enhancement.
44,45 
This type of inflammatory 
demyelinating disease has been termed tumefactive multiple sclerosis, pseudotumoral 
multiple sclerosis, transitional sclerosis, diffuse myelinoclastic sclerosis, Marburg disease or 
variant, and Balo concentric sclerosis. 
 
Fig.1-- The balance between inﬂammation and necrosis and the balance between 
demyelination,remyelination, and axonal loss on the natural history of IIDDs.
46 
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Measures of disease progression — The Kurtzke disability scale, or DSS, and the expanded 
version (expanded disability status scale, or EDSS) are commonly used indices of clinical 
disability in MS.
47,48
 
The time spent by a patient at a given level of disability varies with the score. The median 
time spent with a DSS score of 4 or 5 is 1.2 years, while the median time spent at DSS 1 is 
four years and at DSS 6 three years.
43 
Rate of disability progression — Accumulating evidence suggests that progression of 
disability in patients with MS is slow,
42,49–53
 contrary to the previous studies.
54
 One of the 
largest longitudinal studies followed 2319 patients from British Columbia for 22,723 patient 
years.
52
 Disability scores were prospectively assigned in greater than 95 percent of the 
patients. The following observations were reported
52
: 
 The median time from disease onset to EDSS 6 (cane needed for walking) was 27.9 
years; the median age from birth to EDSS 6 was 59 years. 
 A primary progressive course was associated with more rapid disease progression 
than a relapsing course, and was a risk factor in multivariate analysis for time to use 
of a cane (EDSS 6) from both MS onset (hazard ratio [HR] 2.90, 95% CI 2.39-3.52) 
and from birth (HR 2.68, 95% CI 2.20-3.26) 
 Although men progressed more quickly than women from onset, both men and 
women required a cane at similar ages (58.8 and 60.1 years), and male sex was not 
associated with a worse outcome after controlling for other factors 
10 
 
 Onset of symptoms (eg, motor, sensory, optic neuritis, cerebellar, ataxia, or 
brainstem) did not predict disease progression after controlling for other factors 
 A younger age at onset was associated with slower progression, but patients older at 
onset were consistently older when they progressed to EDSS 6 than patients younger 
at onset. Similar results were found in a large epidemiology study from France .
55
 
Mortality- A longitudinal population-based study from South Wales found that the mean age 
at death was 65 years.
56
Respiratory diseases or infection was the most common cause of 
death. The median survival time from symptom onset was 38 years. The standardized 
mortality ratio was 2.8, suggesting that patients with MS were nearly three times more likely 
to die prematurely than the general population. 
PROGNOSTIC FACTORS — A variety of factors have been identified as possible 
prognostic indicators in MS that may modify the disease course or predict exacerbations. 
Demographic and racial factors  
Relapsing versus progressive phase of disease — The relapsing form of MS is generally 
associated with a better prognosis than progressive disease.
43,50,52
 However, once irreversible 
disability occurred, the time course of progressive disability is similar in the two groups. 
Although not firmly established by the existing evidence, there are data suggesting that most 
patients with relapsing MS will eventually enter a progressive phase of disease.
43,57
 The 
development of a progressive course may be the single most adverse factor influencing 
prognosis.
54,57–63 
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Symptoms at disease onset — Sensory symptoms and Optic Neuritis were thought to have a 
better prognosis than those with pyramidal, brainstem, and cerebellar symptoms.
43
However, 
subsequent data suggested that none of these onset symptoms were independent prognostic 
factors.
52,64
In a systematic review published in May 2005 that evaluated patients with RRMS, 
bowel and/or bladder symptoms at onset had strong and consistent associations with poor 
prognosis. Additional factors that predicted long-term disability in RRMS were incomplete 
recovery from the first attack, a short interval between the first and second attack, and early 
accumulation of disability.
64
 
As compared with monosymptomatic, Polysymptomatic onset was associated with a 
significantly shorter time to the development of progressive disease.
57 
Lesion Volume — Lesion volume at five years and the change during the first five years of 
illness correlated more strongly with disability scores at 14 years suggesting that the 
development of lesions in the early years may have an important influence on long-term 
disability.
65 
DIAGNOSIS —  
The Poser criteria
60
(1980) have been supplanted by the McDonald criteria, which were 
developed in 2001
66
 and subsequently revised in 2005
67
 and 2010
68
. 
McDonald criteria — The McDonald criteria is recently revised in 2010 in order to 
incorporate newer evidence
69–71
and to simplify the use of neuroimaging while preserving the 
sensitivity and specificity of the criteria.
68
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 Dissemination in space- one or more T2 lesions in at least two of four MS-typical regions of 
the CNS (periventricular, juxtacortical, infratentorial, or spinal cord) or by the development 
of a further clinical attack implicating a different CNS site. With brainstem or spinal cord 
syndromes, symptomatic MRI lesions are excluded from the criteria and do not contribute to 
lesion count. 
 Dissemination in time -- Simultaneous presence of asymptomatic gadolinium-enhancing 
and nonenhancing lesions at any time, or a new T2 and/or gadolinium-enhancing lesion(s) on 
follow-up MRI, irrespective of its timing with reference to a baseline scan, or by the 
development of a second clinical attack. 
For PPMS, the criteria require evidence of the 1 year of disease progression (retrospectively 
or prospectively determined) plus 2 of the 3 following criteria (with brainstem or spinal cord 
syndromes, symptomatic MRI lesions are excluded from the criteria and do not contribute to 
lesion count): 
 Dissemination in space in the brain based upon >1 T2 lesions in at least 2 of 4 MS-typical 
regions of the central nervous system (periventricular, juxtacortical, infratentorial, or spinal 
cord) 
 Dissemination in space in the spinal cord based upon 2 or more T2 lesions in the cord 
 Positive CSF findings with isoelectric focusing evidence of OCBs and/or elevated IgG index 
MS attack (also called a relapse or exacerbation) is defined by the McDonald criteria as 
patient-reported or objectively observed event typical of an acute inflammatory 
13 
 
demyelinating event in the CNS, and can be either current or historical, with duration of at 
least 24 hours, in the absence of fever or infection.
68
 
 Paroxysmal symptoms should consist of multiple episodes occurring less than 24 hours.  
For a definite diagnosis of MS to be made, at least one attack must be confirmed by findings 
on either neurologic examination, VEP response in patients with prior visual disturbance, or 
MRI consistent with demyelination in CNS region associated with the prior neurologic 
symptoms. 
The McDonald criteria assign diagnostic confidence as follows
68
: 
 The diagnosis of "MS" is given if the criteria are fulfilled and there is no better 
explanation for the clinical presentation 
 The diagnosis of "possible MS" is given if MS is suspected but the criteria are not 
completely met 
 The diagnosis of "not MS" is given if another diagnosis better explains the clinical 
presentation 
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Magnetic resonance imaging — MRI is the test of choice to support the clinical diagnosis 
of MS.
72
 
Lesion characteristics — The characteristic lesion demonstrated on MRI is the cerebral or 
spinal plaque. Plaques suggestive of MS are typically found in the periventricular region, 
corpus callosum, centrum semiovale, and, to a lesser extent, deep white matter structures and 
basal ganglia. MS plaques usually have an ovoid appearance, and lesions are arranged at 
right angles to the corpus callosum as if radiating from this area. The plaques appear 
hyperintense on proton density and T2-weighted studies, and they are hypointense (if visible 
at all) on T1-weighted images. MRI scanning is more sensitive and specific for predicting 
evolution to clinically definite MS than other studies such as CT scans, cerebrospinal fluid 
parameters, or evoked potentials.
73
 
70
 
Magnetic resonance spectroscopy (MRS) - Chronic MS is associated with a reduction of 
NAA in comparison to Choline and Creatinine within the brain. A reduced NAA/Cr ratio 
implies loss of neurons or axons, which is consistent with pathological studies and appears to 
parallel disability in MS.
74
 
Cerebrospinal fluid analysis — A positive CSF is based upon the finding of either 
oligoclonal bands (OCBs) or by an increased IgG index. An abnormality of CSF IgG 
production as measured by the IgG index or IgG synthesis rate is found in 90 percent of 
clinically definite MS patients.
75
The CSF total leukocyte count is normal in two-thirds of 
patients, exceeds 15 cells/µL in <5 percent, and only rarely exceeds 50 
cells/µL.
76
Lymphocytes are the predominant cell type, the vast majority of which are T cells. 
CSF protein (or albumin) level is usually normal.  
15 
 
Oligoclonal bands — Oligoclonal bands (OCBs) are found in ≥95 percent of patients with 
clinically definite MS.
77
The presence of OCBs in monosymptomatic patients predicts a 
significantly higher rate of progression to MS than the absence of bands: 25 versus 9 percent 
at three years follow-up in one report.
75
However, quantification of OCBs is an insensitive 
prognostic indicator.
78 
Evoked potentials (EPs) — Detection of a subclinical lesion in a site remote from the region 
of clinical dysfunction supports a diagnosis of multifocal MS. The three most frequently used 
EPs are somatosensory (SSEP), visual (VEP), and brainstem auditory evoked potentials 
(BAEP). 
 Patients with clinically definite MS have abnormal VEPs in 85% of cases.
79
 
 SSEPs are abnormal in 77% of patients with MS, including approximately one-half of 
those who do not have sensory signs or symptoms 
 BAEP abnormalities are less frequent in MS than VEP or SSEP abnormalities, being 
present in 67% of patients with MS. 
American Academy of Neurology (AAN) states that VERs are probably useful for 
identifying patients with clinically definite MS, SSEPs are possibly useful, and there is 
insufficient evidence at this time to recommend BAEP as a useful test for diagnostic 
purposes.
80
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Differential diagnosis of multiple sclerosis- 
Various inflammatory or infectious diseases such as systemic lupus erythematosus, Sjögren's 
disease, polyarteritis nodosa, Behçet‘s disease, syphilis, and retroviral diseases may all 
produce multifocal lesions with or without a relapsing-remitting course. Systemic lupus 
erythematosus can present as a recurrent neurologic syndrome before the systemic 
manifestations of this disease appear. Behçet‘s syndrome is characterized by orogenital 
ulcerations; multifocal neurologic findings occur in less than one-third of these patients The 
inherited vasculopathy known as cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL) can likewise produce a pattern of brain 
lesions on MRI that can mimic the pattern seen in patients with MS.  
TREATMENT--- 
Treatment of acute exacerbations of multiple sclerosis 
1. GLUCOCORTICOIDS — Acute attacks of MS are usually treated with glucocorticoids. 
3-7 day courses of IVmethylprednisolone, 0.5 to 1gm daily, with or without a 
short prednisone taper, are used most commonly.
81,82
 On the basis of Class I and Class II 
studies, glucocorticoid treatment has been demonstrated to have a short-term benefit on the 
speed of functional recovery in patients with acute attacks of MS.  It is appropriate, therefore, 
to consider for treatment with glucocorticoids any patient with an acute attack of MS (Type 
A recommendation).
13
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2. PLASMA EXCHANGE - For patients with acute, severe neurologic deficits caused by 
multiple sclerosis who have a poor response to treatment with high-dose glucocorticoids, 
plasma exchange is advocated.
83,84
 
DISEASE MODIFYING THERAPY- 
For patients with RRMS, there are currently seven approved medications that have been shown 
to alter the natural course of the disease. The FDA approved medications include three beta 
interferon (IFNb) formulations, beta-1a(30 μg IM weekly), beta-1a(44 μg thrice weekly)  and 
beta-1b (250μg S/C every other day), Glatiramer acetate (GA), Natalizumab and Mitoxantrone 
and recently oral fingolimod. There is currently no evidence that IFNb,  GA and Natalizumab 
are effective in very aggressive forms of RRMS and progressive disease forms of MS. 
Mitoxantrone is approved for treatment of secondary progressive MS with worsening relapsing 
and progressive relapsing disease course. 
Mycophenolate (MMF)—It is a potent immunosuppressant that is a selective inhibitor of 
inosine 5'-monophosphate dehydrogenase type II. Preliminary studies have shown good 
tolerability and safety when MMF is utilized as monotherapy or in combination with 
interferons or Glatiramer acetate.
85,86
 
Both interferon beta and MMF appeared safe and well tolerated in the majority of patients. 
There was no difference between MMF therapy and the standard regimen of interferon beta 
therapy on the primary safety MRI endpoints of the study. However, the MMF group showed 
a trend towards a lower accumulation of combined active lesions, Gado and T2 lesions when 
compared with interferon beta.
87 
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Azathioprine- Administered at lymphocyte-suppressing doses, is effective in reducing new 
brain inflammatory lesions and is well tolerated.
88–90
In a meta-analysis of five randomized 
controlled trials, azathioprine was associated with a statistically significant reduction in the 
number of relapses during the first, second, and third years of treatment; relative risk 
reductions for these periods were 20, 23, and 18 percent, respectively. Considering the beneﬁt 
and harms, azathioprine is a fair alternative to interferon beta for treating MS. A logical next 
step for future trials would seem the direct comparison of Azathioprine and interferon beta. In 
fact the direct comparison between these two widely used treatments in MS has not been 
made.
91 
One small, open-label study found that Azathioprine up to 3 mg/kg per day was well 
tolerated and reduced the rate of new gadolinium-enhancing brain lesions in patients with 
RRMS.
88 
Cyclophosphamide- monthly intravenous
 
doses influence the frequency and duration
 
of 
episodes of relapsing/remitting multiple sclerosis.
92
The RRMS group benefited the most 
from high dosage cyclophosphamide and had a significant reduction in the flare frequency. 
According to this trial high dose was found ineffective in SPMS.
93 
DMD therapies have known to have short-and medium-term (2–5 years) benefit in reducing 
relapses, disability progression, and appearance of new inflammatory lesions on magnetic 
resonance imaging (MRI).
94–104
It is proposed that the effect of DMD is in initial 
inflammatory phase not in later degenerative phase. The short duration of the randomized 
pivotal MS trials have provided little to no information about benefit from such treatment 
over periods of extended (>5 years) use. 
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MATERIAL AND METHODS 
The inpatient data base of the Department of Neurology at the Christian Medical College, 
Vellore was searched for patients admitted /evaluated with the diagnosis of Multiple sclerosis 
during the period of Jan 1, 2000 to 29
th
 Feb 2012 (12 year period) for inclusion in the study. 
This study is a Clinical Investigator driven study and has been approved by the IRB (No-
7521 dated 5.7.2011) 
The Clinical data included antecedent events, clinical symptoms and signs, detailed imaging 
data with MRI, electrophysiological data including evoked potentials, CSF pattern, treatment 
details and follow up data for response to treatment were entered into a detailed proforma. 
Information was obtained from the outpatient case records, discharge summaries and follow 
up.  
There were a total number of 157 patients who were evaluated during this period and follow 
up details were available for114 patients.   
INCLUSION CRITERIA- 
1. Patients diagnosed to have MS according to Mc Donald`s criteria.68 
2. Multiple sclerosis with minimum 1 years of follow up were included  
EXCLUSION CRITERIA 
1. ADEM, opticospinal form of ADEM, postinfectious encephalitis/ 
encephalomyelitis, acute transverse myelitis (Complete evolution within 24-48 
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hours with complete transaction without evidence of clinical/subclinical 
involvement of any site other than cord.) 
2. Neuromyelitis optica (Revised diagnostic criteria for NMO published in 2006)105 
3. Evidence of causes other than inflammatory demyelination on radiological, 
biochemical and microbiological tests. 
The following definitions were used for the various presentations— 
1. Acute presentation- onset of illness to peak in one week. 
2. Subacute presentation- onset of illness to peak beyond one week  but within 
one month. 
3. Chronic presentation- peak beyond one month. 
4. Encephalitis-like presentation – patients with spectrum of symptoms of 
fever, headache, altered sensorium, seizures (GTCS or Focal) with / without 
focal deficits. 
5. Stroke like presentation- neurological deficit mimicking involvement in a 
vascular territory without preceding headache or encephalopathy. 
6. Tumour like presentation – Predominant headache/vomiting/raised ICT 
features with or without progressive focal deficits. 
7. Optic Neuritis-unilateral or bilateral painless partial or complete loss of 
vision with partial or complete recovery, on follow up. No other local 
pathology of the eye was responsible for the vision loss. 
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8. Optico-spinal presentation – patients who presented with features of 
diminished vision bilaterally or unilaterally in conjunction with features of 
cord involvement. 
9. Myelitis – patients with features suggestive of cord involvement. 
10. Cerebellitis – patient presented only with cerebellar deficits. 
Baseline Evaluation 
The Kurtzke Expanded Disabilty Status Scale (EDSS) was recorded for each patient.
48 
Follow up Evaluation 
During each visit a detailed history was taken and the finding on clinical examination was 
recorded with respect to the progression of symptoms or appearance of new signs. EDSS was 
recorded at each visit. Gadolinium – enhanced MRI of the brain and spine was done as 
required. 
Clinical Relapse: Patient reported symptoms or objectively observed signs typical of an 
acute inflammatory demyelinating event in the CNS, current or historical, with duration of at 
least 24 hours, in the absence of fever or infection. Paroxysmal symptoms (historical or 
current) should however consist of multiple episodes occurring not beyond 24 hours.  If a 
patient had a relapse, the nature of relapse was recorded, MRI was done, Standard therapy for 
relapse was given and the recovery recorded. 
Clinical progression: 
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It was defined as change in EDSS by one point in the absence of relapse 
MRI Technique: 
The imaging data were interpreted by consultant radiologist. MRI sequences of the brain like, 
T1, T2, FLAIR Post Gadolinium (contrast) and cord were studied. In a suspected case of MS, 
double dose of Gadolinium was used occasionally when an active plaque was suspected. 
1) The total number of lesions, their location and size, cerebral atrophy were noted. 
2) The images taken during the first episode and subsequent follow up were studied.  
3) A detail study and comparison of the scans at admission and last follow up was done. 
Progression on MRI 
Progression on MRI was defined as the appearance of a new gadolinium –enhancing lesions 
at a site different from that recorded earlier, appearance of a new T2-W lesion, or increase in 
the size of an older lesion or brain atrophy. 
Comparison of follow up MRI 
The MRI done on follow up was compared to the baseline MRI. The laboratory data from 
Biochemistry, Microbiology and Neurochemistry labs were obtained from the respective 
department records. CSF cells, Proteins and presence of Oligoclonal bands or raised IgG 
levels were noted. The specific tests reviewed included bacterial and fungal cultures from the 
blood and CSF wherever necessary. Vasculitic markers, collagen disease markers, 
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sarcoidosis were ruled out in all the cases. Seropositivity for HIV was looked for. 
Multimodal evoked potentials i.e. visual evoked potentials, brainstem auditory evoked 
potentials and somatosensory evoked potentials (Median and Tibial) reports of all patients 
were reviewed in the electrophysiology lab. The multimodal evoked potentials were done 
with Nicolet Bravo model GT 775 machine. 
The treatment received at acute presentation and maintenance therapy was also noted from 
the records. The comparison between various treatment modalities was done. 
Statistical Analysis- 
We performed descriptive analyses using the Chi-square and Fisher`s exact tests for 
categorical variable and the student`s t test for continuous variable. Statistically significance 
was taken to be at the two-tailed 0.05 level. Multiple binary logistic regressions were done 
for significance. All statistical analyses were performed with the SPSS statistical software 
package version 16 (SPSS Inc. Chicago, Illinois, USA). 
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RESULTS 
 
A total of 157 patients fulfilled the criteria for multiple sclerosis during a study period of 12 
years. The follow up data was available for 114(72.6%) patients. 146(93%) were adults and 
11(7%) were children below the age of 16 years at the time of inclusion in the study.  
The observed MS types were RR 85(54.1 %), PP 24(5.3 %), SP47 (29.9 %), PR 1(0.6 %). 
There is no statistically difference for predlication of MS type with gender. 47(35.6 %) of 
RRMS patient, during follow up has attained SPMS.  
59(37.6 %) patient has Opticospinal syndrome presentation and rest 98(62.4%) has non 
Opticospinal syndrome. In Opticospinal group 4 patients (2.5%) fits in to NMO spectrum of 
disorder. 
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Table -1 Baseline Characteristics of the 157 patients 
 Optico-spinal (n=59) 
(%) 
Nonoptico-spinal (n=98) 
(%) 
Total Number (n=157) 
(%) 
Males 24(40.7%) 47(48%) 71(45.2) 
Females 35(59.3) 51(52%) 86(54.8) 
Adults 52(88.1) 94(95.9) 146(93) 
Children 7(11.9) 4(4.1) 11(7) 
Mean age 27.15(±9.71)(R12-51) 30.7(±10.1)(R8-58) 29.38 ±10.09R8-58) 
Duration of follow up 
Mean 5.95(±5.56)(R1-24) 6.28(±6.7)(R1-33) 6.16 yrs(±6.29)(R1-33) 
 
The mean age is 29.38  10.09(Range8-58) at the time of inclusion of study. The maximum 
number of patients 77(49%) are in 16-33 yr age group. At present the mean age is 38.57  
11.7(Range 15-70).  
71(45.2%)) were males and 86(54.8%) were females in this group. The Female/ Male ratio 
was 1.21. There was no statistically difference between the ages, gender, and year of follow 
up among groups. 
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Table-2 Initial neurologic symptoms 
symptoms No of patients % of patients 
Monosymptomatic 107 68.2 
Polysymptomatic 50 31.8 
Motor weakness 
(Paraparesis-42, Monoparesis-18, 
Hemiparesis-9, Quadriparesis-3)             
72 
45.8 
Brain stem/Cerebellum 51 32.5 
Visual loss 
(U/L Vision-36, B/L vision-6)                                    
42 
26.7 
Sensory symptoms 38 24.2 
Sphincter disturbances 12 7.6 
Others 11 7 
Initial presentation were motor weakness predominates (45.8%) followed by 
brainstem/cerebellar (32.5%) patients. The asymmetrical onset B/L visual loss was seen in 6 
patients. Monosymptomatic presentations were 68.2% while polysymptomatic presentations 
were 31.8%. 
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Table-3 Presentation of total patients during the course of illness 
Presentation 
Optico-
spinal(n=59)(%) 
Nonoptico-spinal 
(n=98)(%) 
Total Number 
(n=157) (%) 
Acute(<1week) 9(15.3) 14(14.3) 23(14.6) 
Sub acute (1wk-1month) 1(1.7) 5(5.1) 6(3.8) 
Chronic(> 1 month) 0 21(21.4) 21(13.4) 
Temporal profile 
(Acute,chronic,subacute) 
49(83.05) 58(59.1) 107(68.1) 
Monosymptomatic 51(86.4) 56(57.1) 107(68.2) 
Polysymptomatic 8(13.6) 42(42.9) 50(31.8) 
Relapsing recurrent 38(64.4) 47((48) 85(54.1) 
Primary progressive 0 24(24.5) 24(15.3) 
Secondary progressive 21(35.6) 26(26.5) 47(29.9%) 
Progressive relapsing 0 1(1) 1(0.6) 
Monosymptomatic presentation was more in Opticospinal group (p=0.000). The Temporal 
profile (Acute, chronic, sub acute) presentation were present more in Optico-spinal group 
(p=0.004). Relapsing recurrent MS is more common in Optico-spinal group (p=0.000) 
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Table-4 Clinical profile of patients during follow up 
Variables 
Optico-
spinal(n=59) 
(%) 
Nonoptico-spinal 
(n=98)(%) 
Total(n=157) 
(%) 
p value 
Stroke like 1(1.7) 8(8.2) 9(5.7) NS 
Hemispheric 0 12(12.2) 12(7.6) 0.005 
Brain stem dysfunction 11(18.6) 32(32.7) 44(27.4) NS 
Cerebellar dysfunction 16(27.1) 42(42.9) 58(36.9) 0.048 
Pyramidal 55(93.2) 81(82.7) 136(86.6) NS 
Sensory 50(84.7) 70(71.4) 120(76.4) NS 
Tumour like 0 2(2) 2(1.3) NS 
Myelitis 58(98.3) 70(71.4) 128(81.5) 0.000 
Optic nerve 58(98.3) 34(34.7) 92(58.6) 0.000 
Diplopia 20(33.9) 21(21.4) 41(26.1) NS 
Oscillopsia 22(37.3) 21(21.4) 43(27.4) 0.031 
Nystagmus 12(20.3) 22(22.4) 34(21.7) NS 
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Variables 
Optico-
spinal(n=59) 
(%) 
Nonoptico-spinal 
(n=98)(%) 
Total(n=157) 
(%) 
p value 
INO 1(1.7) 8(8.2) 9(5.7) NS 
Ophthalmoplegia 1(1.7) 12(12.2) 13(8.3) 0.02 
Facial Myokymia 0 1(1) 1(0.6) NS 
Facial Spasm 0 3(3.1) 3(1.9) NS 
Lhermitte‘s 10(16.9) 14(14.3) 24(15.3) NS 
Uhthoff`s 1(1.7) 4(4.1) 5(3.2) NS 
Trigeminal Neuralgia 4(6.8) 4(4.1) 8(5.1) NS 
Parasthesia,Dysthesia 44(74.6) 63(64.3) 107(68.2) NS 
Sensory symp in face 7(11.9) 12(12.2) 19(12.1) NS 
Bladder-UMN 41(69.5) 57(58.2) 98(62.4) NS 
Bladder-LMN 30(50.8) 39(39.8) 69(43.9) NS 
Constipation 27(45.8) 46(46.9) 73(46.5) NS 
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Variables 
Optico-
spinal(n=59) 
(%) 
Nonoptico-spinal 
(n=98)(%) 
Total(n=157) 
(%) 
p value 
Fecal Incontinence 6(10.2) 6(6.1) 12(7.6) NS 
Bowel bladder 43(72.9) 61(62.2) 104(66.2) NS 
Sexual Dysfunction 7(11.9) 17(17.3) 24(15.3) NS 
Fatigue 42(71.2) 59(60.2) 101(64.3) NS 
Gait involvement 53(89.8) 84(85.7) 137(87.3) NS 
Limb ataxia 14(23.7) 31(31.6) 45(28.7) NS 
Vertigo 9(15.3) 25(25.5) 34(21.7) NS 
Seizures 3(5.1) 6(6.1) 9(5.7) NS 
NS-Not significant 
Hemispheric, cerebellar, ophthalmoplegia were more common in NOSMS, while 
myelopathy, optic neuropathy were commoner in OSMS. 
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COURSE OF THE DISEASE- 
The follow up data was available for 114(72.6%) patients. 
Number of Episodes – 16(14%) had 1 episode, 23(20.2%) had 2 episodes, 41(36%) had 3 
episodes and 20(17.5%) had 4 episodes of illness. The annualized relapse rate (ARR) is 0.35 
/yr 
Mean number of episodes was 3±1.36 in our study. The Range was 8(1-9). The second 
episode occurred 1.62±1.96 yr (Range0.1-12 yrs) after the first one. The recovery was 
complete in 109(69.4%) patients after first episode. 
MULTIMODAL EVOKED POTENTIALS IN THIS STUDY 
 Data is not available in 5 patients. VEP, SSEP Tibial, SSEP Median, BAER, was 
done in 95.5%, 87.3%, 59.8%, and 43.9% respectively. 
 VEP- 59.3% (89/150) had bilateral abnormality; 18.6% (28/150) had unilateral 
abnormality. 
 67.3% (93/138) had abnormal tibial SSEPs  
  51.1% (48/94) had abnormal median SSEPs.  
 39.1% (27/69) had abnormal BAER findings. 
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CSF Abnormalities in Study 
 55.4 %( 87/157) has CSF cell and protein value within normal range. 
Table-5 CSF analysis 
 No of patients % of patient 
CSF protein 45-90mg% 47 29.9 
CSF protein <45mg% 110 70.1 
CSF Cells10-25 29 18.5 
CSF Cells 25-50 6 3.8 
CSF cells<10 122 77.7 
OCB present 53 36.3(53/146) 
OCB data not available 11 7 
In the OSMS and NOSMS the OCB was positive in 39 %( 22/56) and 34.4 %( 31/19) and 
there was no statistically difference among groups. 
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MRI scan Studies 
All the patients had abnormalities in the MRI of the brain and 134(85.3%) abnormalities 
were detected on the spinal cord imaging. > 15 lesions were found in 140(89.2%) patients. 
Ten (6.4%) patient`s MRI showed spinal cord hyper intensity involving >3 vertebral 
segments. 
Table-6 MRI studies 
Sites No of patients % of patients 
Periventricular 150 95.5 
Juxtacortical 147 93.6 
Infratentorial 103 65.6 
Callosal and Pericallosal lesions 98 62.4 
Dawson`s finger 50 31.8 
Brain stem 98 62.4 
Cerebellum 47 29.9 
Cerebellar  Peduncle 38 24.2 
Thalamus 23 14.6 
Basal ganglia 19 12.1 
Cervical cord 126 80.3 
Thoracic cord 93 59.2 
Cervico thoracic cord 80 51 
Gadolinium enhancement 48 30.6 
The most common location of lesions were periventricular (95.5%), Juxtacortical (93.6%), 
Infratentorial (65.6%). Dawson`s finger were observed in 31.8%. 
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The size of brain lesion were <3 cm in 151(96.2 %) patient. 5(3.2 %) has 3-5 cm brain lesion 
and 1 patient has 6 cm brain lesion. 
Follow up MRI was done in mean year of 1.88±2.35 years (Range-0.2-13). The follow up 
MRI data was not available in 44(28 %) patients. Improvement was noted in 24(21.2 %) 
patient and worsening in the MRI parameters (increase in number, size, gado enhancement) 
were observed in 43(38.05 %). There was no appreciable changes were noted in 46(40.7 %)  
Cerebral atrophy was noted in 82(52.2 %) patient.  The first scan revealed cerebral atrophy in 
60 patients and 22 patients in follow up studies. Most common type of atrophy is sub cortical 
62/82(75.6 %). Cortical, sub cortical and callosal atrophy was noticed in 20 patients (24.6%) 
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Table-7 Treatment received in acute phase and as DMDs 
Treatment No of patients % of patients 
Acute treatment-MP 147 93.6 
IVIG+ MP 8 5.1 
Plasmapheresis 5 3.2 
ACTH 1 0.6 
Pulse IV Methylprednisolone 68 43.3 
Oral steroid 14 8.9 
Azathioprine 68 43.3 
Mycophenolate 85 54.1 
Cyclophosphamide 23 14.6 
Mitoxantrone 5 3.2 
INF 13 8.3 
Glatiramer 4 2.5 
Methotrexate 3 1.9 
The most common immunomodulatory agent is MMF (54.1%) followed by AZT (43.3%). 
INF most commonly received was interferon β-1a. 
Presently 9.6 %( 11/114) patients is not receiving any treatment and 3.5 %( 4/114) is taking 
alternate preparations. The pulse methyl prednisolone (weekly tapering schedule) was given 
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for mean 15.2±7.5 weeks. Inj cyclophosphamide (700-1000mg/m
2)
 was given as monthly 
pulses for mean of 10.68±3.3. Earlier the standard of practice was treatment with 
azathioprine. However the azathioprine was switched over to Mycophenolate in 17.6% 
(12/68) patients due to clinical worsening. 
OUTCOME ANALYSIS 
The patients presented to us after a mean of 3.8±3.59 yrs (range-0.1-19) following the first 
episode. EDSS of patients at presentation was with mean 4.4±1.31 (Range 1-8). The mean 
duration of follow up for 114 patients was 6.16±6.29 years (range 32 years 1-33). During the 
last follow up the EDSS was mean 4.1±2.31 (range 0-10) 
For outcome analysis two groups has been divided based on final follow up EDSS as ≥6 and 
<6 on basis of requirement of support for ambulation. 
 In view of Opticospinal syndrome can be of NMO spectrum of disorder and as we have not 
done NMO antibody for most of the patients, for final outcome analysis we have divided to 
Opticospinal MS (OSMS) and nonoptico-spinal MS (NOSMS). One patient has death due to 
accidental cause was not included in the final outcome. One patient has death due to 
respiratory failure attributable by significant cervico-medullary lesion. 
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Figure-2 Final outcome analysis 
 
 
 
 
 
 
 
 
 
 
 
The difference in outcome for OSMS and NOSMS is not stasttically significant as p= 0.282
Total No of 
Patient-157 
Optico-Spinal 
59(37.6%) 
Non Opticospinal 
98(62.4) 
Follow up data 
45(76.3%) 
Follow up data 
69(70.4%) 
EDSS < 6 
36(80%) 
EDSS ≥ 6 
9(20%) 
EDSS < 6 
49(71%) 
 
EDSS ≥ 6 
20(29%) 
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Table-8.1 Outcome analysis of total patients (n=114) 
Out come 
EDSS <6 
(n=85) 
EDSS ≥6 
(n=29) 
Unadjusted Adjusted 
No % No % OR 95%CI p OR 95%CI p 
Male 33 33.8 14 48.3 1.471 .62-3.43 .37    
Female(Ref) 52 61.2 15 51.7    
SP+PP 23 27.1 25 86.2 16.4 5.28-53.68 .00 3.51 2.28-79.8 .004 
RR(Ref) 62 72.9 4 13.8 
Recovery after 1
st
 episode-complete 67 84.8 13 56.5 .233 .083-.651 .005 .46 .09-2.18 .331 
Presenting symp-Motor 28 32.9 15 51.7 2.18 .92-5.14 .075    
Presnting symp-Sphincter disturb 1 1.2 4 13.8 13.44 1.43-125.7 .023    
Polysymptomatic 16 18.8 16 55.2 5.3 2.1-13.2 .000 2.86 .54-15.07 .214 
Monosymptomatic(Ref) 69 81.2 13 44.8 
Cerebellar 30 35.3 17 58.6 2.59 1.09-6.15 .030 .264 .042-1.65 .155 
U/L ataxia 19 22.4 15 51.7 3.72 1.52-9.05 .004    
Optico-spinal 36 42.4 9 31 0.613 .25-1.501 0.28    
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Out come 
EDSS <6 
(n=85) 
EDSS ≥6 
(n=29) 
Unadjusted Adjusted 
No % No % OR 95%CI p OR 95%CI p 
Bladder-UMN 48 56.5 24 82.8 3.7 1.28-10.62 .015 1.34 .21-8.57 .752 
Bladder- LMN 30 35.3 20 69 4.07 1.65-10.05 .002    
Constipation 32 37.6 21 72.4 4.34 1.65-10.05 .002    
Faecal urge incontinence 2 2.4 4 13.8 6.64 1.14-38.4 .035    
Sexual dysfunction 8 9.4 7 24.1 3.06 1.14-38.4 .05    
Pyramidal affection 69 81.2 28 96.6 6.49 .82-51.32 .076    
MRI-cerebellar lesion 20 23.5 13 44.8 2.64 1.08-6.44 .032 3.23 .703-14.87 .132 
During the presentation the symptoms like visual, sensory, brain stem, cerebellar, does not help in predicting worse out come. The 
analysis for gender, stroke like, brain stem, hemispheric, Optico-spinal, myelitis, tumor like, optic neuropathy, Diplopia, 
Oscillopsia, Nystagmus, INO, ophthalmoplegia, facial myokymia, facial spasm, facial sensory loss, Lhermitte`s, Uhthoff`s, 
Trigeminal neuralgia, parasthesia , dysesthesia , fatigue, vertigo, seizures symptom analysis is not having statistically significant 
difference as p>0.05. 
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Table-8.2 Outcome analysis of total patients (n=114) 
Out come EDSS <6 
(n=85) 
EDSS ≥6 
(n=29) 
unadjusted Adjusted 
No % No % OR 95%CI p OR 95%CI p 
MRI-Basal ganglia lesion 2 2.4 5 17.2 8.64 1.57-47.4 .013    
MRI-Cerebral atrophy 34 40 25 86.2 9.37 2.99-29.34 0.000 4.508 .78-25.92 .092 
Pulse IV MP 50 58.8 14 48.3 1.607 .688-3.75 .273    
Mycophenolate 63 74.1 13 44.8 .284 .11-.683 .005 .993 .236-4.171 .992 
Azathioprine 24 28.2 14 48.3 2.37 .996-5.65 .051 2.707 .62-11.81 .185 
First EDSS>6 5 5.9 12 41.4 11.29 3.51-36.2 0.000 2.23 .42-11.62 .339 
First EDSS<6 80 94.1 17 58.6 
 
Progressive form of MS(PP,SP) were having significant worse outcome(OR-3.51,95%CI-2.228-7.98,p=0.004) comparing to 
relapsing MS after analyzing by multiple logistic regression taking other variables like complete recovery after first episode, 
poly/mono symptomatic, cerebellar, bladder-UMN, MRI-Cerebellar lesion, MRI-brain atrophy, MMF, AZT . Other risk factors 
were statistically significant in univariate but lose significance with multivariate method. However odd`s ratio and 95% CI signify 
their prognostic role. Treatment with Mycophenolate was associated with good outcome (OR-0.284,95%CI-0.11-0.683,p=0.051) 
in univariate analysis. The cyclophosphamide and Mitoxantrone was associated with worse prognosis most probably related to 
patient selection.  The AZT is having  no statistically protective role (OR-2.707,95%CI-.622-11.81,p=0.185) 
CSF analysis and evoked potential did not predict about worse outcome. 
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Table-9.1 Outcome analysis of non optico-spinal group (n=69) 
Out come EDSS <6 
(n=49) 
EDSS ≥6 
(n=45) 
Unadjusted Adjusted 
No % No % OR 95%CI p OR 95%CI p 
Male 19 38.8 10 50 1.57 0.55-4.504 .393    
Female(Ref) 30 61.2 10 50    
SP+PP 15 30.6 17 85 12.84 3.26-50.52 .000 2.88 .54-15.36 .214 
RR(Ref) 34 69.4 3 15 
Recovery after 1
st
 episode-
complete 
37 86 7 50 .162 .042-.63 .009    
Presenting symp-Motor 17 34.6 13 65 8.47 .824-87.04 .072    
Presnting symp-Sphincter 
disturb 
1 2 3 15   .037    
Polysymptomatic 11 22.4 14 70 8.06 2.506-25.92 0.000 3.73 .94-14.79 .061 
Monosymptomatic(Ref) 38 77.6 6 30 
Cerebellar 19 38.8 14 70 3.684 1.207-11.24 .022 1.36 .29-6.28 .69 
U/L ataxia 10 20.4 12 60 5.85 1.88-18.15 .002    
Bladder-UMN 25 51 18 90 8.64 1.807-41.3 .007 3.67 .58-23.17 .166 
Bladder- LMN 15 30.6 14 70 5.28 1.703-16.42 .004    
constipation 18 36.7 15 75 5.16 1.608-16.59 .006    
During the presentation the symptoms like visual, sensory, brain stem, cerebellar, does not help in predicting worse out come. The 
analysis for gender, stroke like, brain stem, hemispheric, myelitis, tumour like, optic neuropathy, Diplopia, Oscillopsia, 
Nystagmus, INO, ophthalmoplegia, facial myokymia, facial spasm, facial sensory loss, Lhermitte`s, Uhthoff`s, Trigeminal 
neuralgia, parasthesia , dysesthesia , faecal incontinence, sexual dysfunction, fatigue, vertigo, seizures , no of episodes analysis is 
not having statistically significant difference as p>0.05 
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Table-9.2 Outcome analysis of non optico-spinal group (n=69) 
Out come EDSS <6 
(n=49) 
EDSS ≥6 
(n=20) 
Unadjusted Adjusted 
No % No % OR 95%CI p OR 95%CI p 
Gait 36 73.5 20 100 6.86 .83-56.5 .073    
Pyramidal 35 71.4 19 95 7.6 .92-62.3 .059    
MRI-cerebellar lesion 12 24.5 10 50 3.083 1.035-9.188 .043    
MRI-basal ganglia lesion 1 2 5 25 16 1.73-147.8 .015    
MRI- cerebral atrophy 20 40.8 18 90 13.05 2.72-62.6 .001    
MMF 36 73.5 12 60 1.113 .28-4.31 .877    
AZT 14 28.6 10 50 2.35 .63-8.73 .22    
First EDSS<6 4 8.2 12 60 7.5 1.92-29.8 .004 1.78 .308-10.29 .518 
First EDSS>6(Ref) 45 91.8 8 40 
 MS type, poly/mono symptomatic, cerebellar, bladder-UMN, EDSS at first visit were statistically significant in univariate but lose 
significance with multivariate method. However odd`s ratio and 95% CI signify their prognostic role. Treatment with 
Mycophenolate is not statistically significant. (OR-1.113, 95%CI-0.28-4.31, p=0.877) in univariate analysis. 
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Table-10.1 Outcome analysis of optico-spinal group (n=45) 
Out come 
EDSS <6 
(n=36) 
EDSS ≥6 (n=9) Unadjusted Adjusted 
No % No % OR 95%CI p OR 95%CI p 
Male 14 38.9 4 44.4 1.27 .28-5.49 .76    
Female(Ref) 22 61.1 5 55.6    
SP+PP 8 22.2 8 88.9 28 3.03-258.4 .003 12.75 .76-213.2 .076 
RR(Ref) 28 77.8 1 11.1 
Recovery after 1
st
 episode-
complete 
37 86 7 50 .162 .042-.63 .009    
Polysymptomatic 5 13.9 2 22.2 1.77 .28-11.08 .541    
Monosymptomatic(Ref) 31 86.1 7 77.8 
Cerebellar 11 30.6 3 33.1 1.13 .24-5.39 .872    
Bladder-UMN 23 63.9 6 66.7 1.13 0.24-5.29 .876    
Bladder- LMN 15 41.7 6 66.7 2.8 .603-13.01 .189    
constipation 14 38.9 6 66.7 3.14 .674-14.6 .145    
Urge incontinence 1 2.8 2 22.2 10 .793-126 .075    
Sexual dysfunction 3 8.3 2 22.2 3.143 .44-22.4 .254    
Cerebellar 8 22.2 3 33.3 1.750 .35-8.6 .49    
Because of less number of patients in OSMS group, only 4 variables were analyzed in multivariate model. MS type, MRI- cerebral 
atrophy, MMF, EDSS at first visit were statistically significant in univariate but lose significance with multivariate method. 
However odd`s ratio and 95% CI signify their prognostic role.  
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Table-10.2 Outcome analysis of optico-spinal group (n=45) 
Out come EDSS <6 
(n=36) 
EDSS ≥6 (n=9) Unadjusted Adjusted 
No % No % OR 95%CI p OR 95%CI p 
Cerebral atrophy 14 38.9 7 77.8 5.5 .99-30.36 .05 1.3 .119-14.2 .829 
MMF 27 75 1 11.1 .04 .005-.38 .005 .15 .013-1.95 .15 
AZT 10 27.8 4 44.4 .481 .107-2.16 .34    
First EDSs >6 35 97.2 5 55.6 28 2.58-303.5 .006 8.32 .41-168.6 .167 
First EDSS <6 1 2.8 4 44.4 
Treatment with Mycophenolate is statistically significant. (OR-0.005,95%CI-0.005-0.38, p=0..005) in univariate analysis. It 
signify better role of MMF in OSMS than NOSMS.  
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DISCUSSION 
The prevalence of MS in India is approximately 1.33/100,000 as reported by Singhal 
9
 in the 
mid eighties from the west coast of India. Study from the France suggested the estimated 
prevalence was 188.2 cases per 100,000 inhabitants (95% CI: 182.7; 193.8), and the 
estimated annual incidence was 8.5 cases per 100,000 inhabitants (95% CI: 7.3; 9.7).
106
 Over 
the last one decade, Indian hospital-based studies have shown that, the total proportion of 
MS-related neurology department admissions increased from 1.58% to 2.54%.
7
 Our study 
depicts MS admission rate as 1.02%. Geographically north west India (above 15◦ N latitude) 
has 4.15 new cases of MS per year as compared to 3.2 cases per year from south India (below 
15◦ N latitude).107 Previously the diagnosis of multiple sclerosis was based on clinical, 
electrophysiology, CSF analysis but recently neuroimaging has utmost role. We have 
selected our cases based on recent McDonald`s criteria.
68
 
In the present study the age of onset was 29.38 (±10.09) which is comparable to other Indian 
studies.
5,108
 The youngest and oldest case reported in the present study were 8 and 58 years 
old respectively. The mean age in PPMS group is 33.38 ±8.18 years which is higher 
comparing to other groups and also recognized in other studies.
109
 Eleven (7%) were children 
below the age of 16 years at the time of inclusion in the study which is in accordance with 
previous studies.
110,111
   
The female to male ratio was 1.21, which is in agreement with the other studies reported 
from India.
6,7
  Some of the previous Indian studies reported also a higher male ratio. (4, 10) 
Increase in literary awareness of medical illnesses in our country is probably responsible for 
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more females being diagnosed as MS. The annualized relapse rate (ARR) is 0.35 /yr which 
are comparable to the results found in previous studies. 
112,113
 
In this study, motor weakness was the commonest initial symptom (45.8%) followed by 
visual impairment (26.7%) and sensory parasthesia (24.2%). These features correlate well 
with other studies from India
108,114
 which documented weakness as the commonest initial 
presentation similar to western pattern.
59
 Though MS in India is not different from the 
western variety,
108
 an increased frequency of visual involvement is a common feature in 
Asian variety. 
3,115
 Other Indian studies depict visual symptoms as predominant presenting 
complaint.
3,6,116
 Visual impairment in Japanese and ataxia in western reports were relatively 
more commoner than Indian series. 
 These subtle but important differences between different geographical regions within the 
same country suggest that genetic and environmental factors play an important role in the 
manifestation of MS. The series from different parts of the country (mostly cross sectional) 
did not use a common protocol which may account for variation. 
Our study showed Pyramidal (86.6%), sensory (68.2%) and bowel and bladder (66.2%) 
involvement predominate the symptoms/signs observed during the course of illness whereas 
optic nerve involvement was seen in 58.6% cases.  
A major difference in Caucasians and Oriental series has been the incidence of cerebellar 
involvement which was found in over 80% in the former
117,118
 and 30-58% in the 
latter
5,10,108,119
. In the present study, cerebellar involvement was 36.9 %.  
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Seizures are uncommon presentation of MS and were noted in nine patients (5.7%) in the 
present series which was in accordance to the literature with  2.3-5%.
6,120–122
 Internuclear 
ophthalmoplegia (INO) was seen in 9 cases (5.7%) in the present series which was also 
observed in 6.66% patients in the Gangopadhyay series.
6
 
CSF analysis showed mild abnormality (cells>10, Protein>45mg %) in 44 .5%  of patients. 
There was no significant co-relation between severity of abnormality in the CSF and final 
outcome as measured by EDSS at final visit.  
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Table No-11  Overview of common features of clinical observational follow –up case 
series of MS compared with our study. 
Author/Ref
erence No. 
Jain
12
3
 
Sayal
7
 
Mani
124
 Gangop
adhyay
6
 
Ban
sil
10
 
Sarma G 
R K
116
 
Kalani
e
109
 
Renouxl
125
 
Our 
study 
Year 
covered by 
study 
1957-
1980 
1986-
1998 
1991-
1996 
1989-
1999 
199
0s 
1987-1997 1996-
2001 
1976-
2001 
2000-
2012 
Population Indian Indian Indian Indian Indi
an 
Indian Iranian Europe Indian 
No of 
Patients 
354 100 31 45 81 68 200 684 157 
Mean age of 
onset(years) 
27 28.5 25.3 30.5 27.
5 
26.3 27 13.7±2.4 29.3 
Male:Femal
e 
1:1.32 1:1.32 1:2.10 1:1.50 1:2.
25 
1:2.1 1:2.50 1:2.78 1:1.18 
Optico-
spinal 
presentation 
(%) 
22-58 47 23 33 NA 25-36 20 NA 37.6 
Follow up in 
yrs 
NA NA NA NA NA 0.5-10 NA 25 1-33 
Initial 
Neurologica
l Symp(%) 
NA Pyram
idal 
inv(46
.4) 
Visual 
loss(47) 
Visual 
loss(53.
3) 
NA Visual 
loss(44.1) 
Pyrami
dal 
Visual 
loss(23.4
) 
Pyramida
l(45.8) 
Most 
common 
Sign during 
follow up 
NA Pyram
idal(8
7) 
Visual 
impairm
ent(77) 
Pyramid
al(93.3) 
NA  
Visual 
pathway(4
4.1%) 
NA NA Pyramida
l(86.6) 
NA- data not available 
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Multimodal evoked potentials were done in to look for subclinical anatomical affected sites 
of demyelination. In our series VEP showed 59.3 %(B/L),18.6% (U/L)abnormality. Other 
EPs with abnormalities were 67.3%, 51.1% and 39.1% in tibial SSEPs, median SSEPs. 
BAEP respectively.  These evoked potential analysis were similar to previous studies.
73
 
Thus, Evoked potential studies did not predict  worse outcome.  
All the patients‘ had abnormalities in the MRI of the brain and in 85.3% (134/157) 
abnormalities were detected in the spinal cord imaging. The most common locations were 
periventricular (95.5%), juxtacortical (93.6%), infratentorial (65.6%) and spinal cord 
(85.3%). The high frequency of MRI abnormalities were because of strict adherence to recent 
McDonald`s criteria.
68
 The cerebral atrophy was noted more in the EDSS group >6 (86.2% 
c/w41.2%, p=0.000). The lesion load has not significant correlation with outcome analysis. 
Previous studies showed brain atrophy had a stronger association with physical disability 
than T1 hypointense(black hole) and T2 hyperintense lesion load.
126,127
.Gado enhancing 
lesions were noted in 48(30.6%) patient, but did not predict worse outcome. A Meta-analysis 
study demonstrated that Gado enhancement predicts the occurrence of relapses, but it is not a 
strong predictor of the development of cumulative impairment or disability.
128
 The cerebellar 
and basal ganglia lesion were associated with worse outcome. 
37.6 %( 59/157) of the study group had optico-spinal presentation. There is literature on high 
frequency of optic and spinal cord involvement in several Indian studies
122
  and Japan 
studies.
4
 Optico-spinal MS, with attacks restricted clinically to spinal cord and optic nerve 
were seen in 20-60% of cases.
129
 Pandit et al 
130
 found 47% of their MS cases to have clinical 
attacks confined to the optic nerve and spinal cord. A paper by Jain et al 
123
 has been widely 
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quoted in western literature as evidence for high prevalence of NMO in India. With the 
recent Wingerchuk criteria
105
 for NMO and testing facility for  NMO antibody, more number 
of patients  in the OSMS could be diagnosed to have NMO. With this background, in our 
study, we have taken the optico-spinal group separate from the nonoptico-spinal presentation. 
Since, we have been doing NMO antibody in the last 3-4 years; we classified the total group 
as Opticospinal MS (OSMS) and nonoptico-spinal MS (NOSMS) for final outcome analysis. 
This is corroborated by treatment response to MMF, with the OSMS group having a better 
outcome. 
A number of clinical factors were analyzed, with respect to their validity in assessing the 
long-term prognosis. In our study the course of the disease was dependent on the onset 
characteristics, with primary progressive patients experiencing a much more severe course. 
In patients with an acute onset and complete recovery from first attack were significantly 
associated with a favorable long-term prognosis. Weinshenker et al has described that 
women, young age at onset, and without motor onset symptoms were more likely to be 
considered benign.
131
 The factors negatively influencing the prognosis were male sex, age at 
onset over 25, pyramidal involvement ,more functional systems affected at onset or after 5 
years and incomplete first remission.
132
 In our study the polysymptomatic presentation, 
motor, pyramidal involvement and sphincter symptoms at onset had poor outcome. The 
bowel- bladder symptoms, sexual dysfunction, Cerebellar dysfunction were having worse 
prognosis  looking at the  natural history of the disease , similar to other studies.
43,133
  
The relapse rate in our study was 3±.36, which did not correlate with outcome, as 
demonstrated earlier.
134
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Two Indian studies have narrated experience of beta interferon
11
 and Mitoxantrone
12
 
recently. Standard of care provided in our study was IV methylprednisolone for acute attacks 
and relapses and the DMD‘s used were AZT (43.3%) and of recently, MMF (54.1%). MMF 
was associated with significant better outcome in patients in our study (O.R-0.284(C.I-0.11-
0.683) p=0.0051. in univariate analysis.  Preliminary studies have shown good tolerability 
and safety when MMF is utilized as monotherapy or in combination with INF or GA.
85,86
 
In our study the EDSS of patients at presentation was 4.4±1.31 and at final follow up after 
6.16±6.29 years is 4.1±2.31. The median EDSS score was 2.1 in Iran at 5.5years
109
 and 3.7 in 
Gangopadhyay et al series after 6 years post onset
6
.  In our study benign MS (EDSS≤6) are 
29(18.5%). Earlier Literature suggests that progression of disability in patients with MS is 
slow
42,49–53
 contrary to the some studies.
54
 The British Columbia study
52
 showed the median 
time from disease onset to EDSS 6 was 27.9 years and the median age from birth to EDSS 6 
was 59 years. So, epidemiological study on a long term basis is required for proper analysis 
of disability progression.  The limitations of the study were Retrospective nature, short 
duration of follow up and small number of patient. Survival analysis (Kaplan Meir) could not 
be done for statistical outcome in view of retrospective nature of this study. 
In future long term prospective study is suggested for proper analysis of natural history of 
multiple sclerosis.  It would be appropriate to have future trials with DMDs like 
Mycophenolate and to have a head to head comparison with interferon beta and Glatiramer 
acetate. This would be of relevance in the developing world resource crunch setting, where 
health insurance is not available to most of the population and hence treatment is out of pocket 
payment. 
52 
 
The present study highlights the regional and racial variations in the clinical, imaging and 
laboratory profile of multiple sclerosis.  In our group of patients the salient findings were 
high incidence of optico-spinal presentation, predominance of relapsing remitting form and 
low yield of CSF studies. A notable feature is the analysis of prognostic markers of disability 
progression. The predictors of outcome is about combination of  initial demographic and 
clinical finding with measures of early disease activity and course evaluated clinically along 
with imaging can be used to predict outcome. There is a definite need for a good marker for 
disease activity, help decide form of DMDs and predict response to treatment outcome. 
Future Directions- There is a need for epidemiological study to look at the disease 
prevalence and incidence. It is important to interpret the Opticospinal MS which has been 
reported to be the Asian MS, in the light of Modified Wingerchauk criteria(2006)
105
 and 
NMO antibody. There is a definite need to ideally do randomized double blind control trials 
comparing the DMDs like Mycophenolate with IFN/ Glatiramer acetate in the developing 
world setting. Open label studies using Mycophenolate need to be done, if there are ethical 
issues regarding withhold of standard FDA approved DMDs. 
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CONCLUSION 
 Over a study period of 12 years, there were 157 patients with female preponderance. 
The observed MS types were RR 85(54.1 %), PP 24(5.3 %), SP47 (29.9 %), PR 1(0.6 
%). 59(37.6 %) patient has Opticospinal syndrome presentation and rest 98(62.4%) 
has non Opticospinal syndrome. 
 47(35.6 %) of RRMS patient, during follow up has attained SPMS. 
 EDSS of patients at presentation and at final follow up after 6.16±6.29 years was 
4.4±1.31 and 4.1±2.31 respectively. .  In our study benign MS (EDSS≤6) are 
29(18.5%). 
 Progressive form of MS (PP, SP) were having significant worse outcome (OR-3.51, 
95%CI-2.228-7.98,p=0.004) when compared to RRMS . 
 At first presentation the factors: incomplete recovery, polysymptomatic symptoms 
like motor, sphincter involvement and during the disease course bowel, bladder, 
cerebellar and pyramidal involvement were predictors of poor outcome.(Univariate 
analysis) 
 The age, gender, number of episodes, Optico-spinal presentation were not statistically 
related to outcome analysis.  
  Treatment with Mycophenolate is having good outcome (O.R-0.284(C.I-0.11-0.683) 
p=0.0051. in univariate analysis.  The OSMS group had a better outcome with 
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Mycophenolate when compared to NonOSMS group, suggesting that this probably 
represents the NMO spectrum.  
 The presence of cerebral atrophy and cerebellar involvement showed positive 
correlation with disability progression.  
 CSF OCB was positive in 36.3%. 
 There is a definite need for a good marker for disease activity, help decide form of 
DMDs and predict response to treatment outcome. 
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 APPENDIX 
Appendix 1  
PROFORMA FOR THESIS 
Longitudinal Follow up study of patients with Multiple sclerosis: Experience from a 
Tertiary Care Hospital --- 
PATIENT – 
Name   - 
Age /Sex - 
Address - 
H.NO   - 
DOA   - 
Types: Relapsing-remitting  
            Primary-progressive  
            Secondary-progressive  
            Progressive-relapsing 
 Clinical Details of Relapse - 
Acute/Sub acute/ 
Preceding fever -Yes/No 
Preceding vaccination –Yes/No 
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Clinical Features: 
Sensory in limbs 
Sensory in face 
Motor (sub acute)  
Motor (acute) 
Co-ordination: Gait disturbance/ Limb ataxia/Slurred Speech/Tremor 
Vertigo 
Visual disturbances: Visual loss/ Diplopia/Oscillopsia/Nystagmus/ Internuclear 
ophthalmoplegia 
Pain: Lhermitte's sign /Trigeminal Neuralgia/ Dysesthetic pain/Visceral pain/Painful tonic 
spasms 
Bladder problems: Urgency/ Incontinence/ Others 
Bowel: Constipation/ Incontinence 
Sexual Dysfunction 
Fatigue 
Uhthoff's phenomenon  
Seizures 
Higher Functions: Attention span / concentration / recent memory / Abstract 
Conceptualization / Speed of information processing / dementia 
Psychiatric disorder: manic depression, paranoia, major depression 
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Paroxysmal symptoms: 
Facial myokymia 
Hemi facial spasm 
Others 
Past Illness/Co-morbidities:  
Other Autoimmune disease: 
Recent Vaccinations/Viral infections 
Sun Exposures 
Smoking 
Psychosocial Stress: 
Month of birth: 
Presentation – Monosymptomatic / Polysymptomatic onset 
Stroke like 
Brainstem- 
Cerebellar – 
Hemispheric - 
Encephalitic - 
Myelitis - 
Tumour like – 
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SITE OF NEURAXIS 
 Optic Neuritis – 
 Spinal  
 Hemispheric 
 Ataxia 
Course of disease - 
 Relapses- Number, Change in disability status  
 R-R 
 S-P 
 PP 
 PR 
 Functional Systems:  
 pyramidal  
 cerebellar  
 brainstem  
 sensory  
 bowel and bladder  
 visual  
 cerebral  
 other  
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Total number of Episodes- …….. 
DISABILITY SCORE   
EDSS at presentation - 
EDSS at Discharge - 
EDSS at final follow up – 
Duration of last follow up - 
 
CSF CHARACTERISTICS 
Cells:  TWBC :                  L :                       N:                               RBCS: 
 Proteins: 
Sugars: 
OCBs : 
Others :  
IMAGING CHARACTERISTICS 
At Presentation 
Total Lesions(Brain + cord) - 
Solitary - 
Unilateral - 
Bilateral - 
Multiple - 
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Size  > 3 cm - 
Subcortical – 
Deep cortical - 
Periventicular - 
Corpus Callosum – 
Centrum semiovale- 
Middle Cerebellar Peduncle - 
Brainstem - 
Basal Ganglia - 
Thalamus - 
Gado enhancement – yes/no / not done /  
Pattern of enhancement – 
Brain Atrophy: 
Spinal cord 
Spinal cord swelling- Yes/No 
Size: 
Part of cord involvement: 
 Cervical + dorsal cord - 
> 3 segment – 
Gado. Enhancement – yes / no / not given 
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Last Imaging - 
No follow up Imaging - 
Total Lesions (Brain + cord) - 
Solitary - 
Unilateral - 
Bilateral - 
Multiple - 
Size > 3 cm - 
Subcortical – 
Deep cortical - 
Periventicular - 
Corpus Callosum – 
Centrum semiovale- 
Middle Cerebellar Peduncle - 
Brainstem - 
Basal Ganglia - 
Thalamus - 
Gado enhancement – yes/no / not done /  
Pattern of enhancement – 
Spinal cord 
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Spinal cord swelling- Yes/No 
Size: 
Part of cord involvement: 
 Cervical + dorsal cord - 
>3 segment - 
> 3 segment – 
Gado. Enhancement – yes / no / not given 
No. of New lesions – 
Site of new lesions – 
Complete Resolution – 
 Partial Resolution – 
Worsening – 
MULTIMODAL EVOKED POTENTIALS  
VEPs - Normal     Not done           Abnormal unilaterally            Abnormal Bilaterally 
BAER- Normal    Not done           abnormal  
SSEPs –            
Median -- Normal      Not done            Abnormal 
Tibial -- Normal        Not done        Abnormal 
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TREATMENT DETAILS 
ACUTE – 
IVIg - 
Methylprednisolone - 
MPS + IVIg – 
Alternative forms of treatment 
No treatment - 
MAINTANANCE –  
Tab.Azathioprine   - 
Tab.Mycophenolate - 
Inj.Cyclophosphamide pulse doses – 
Alternate forms of treatment 
No Treatment - 
Others - 
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Appendix 2 
PATIENT’S INFORMATION AND INFORMED CONSENT  
 I understand that the department of Neurological sciences is doing a study:  
To study the Clinical Profile, Imaging, Electrophysiological and CSF characteristics with 
special reference to outcome in a cohort of patients diagnosed to have Multiple Sclerosis in 
the Department of Neurology at CMC, Vellore, during a period of 12 years (2000-2012). The 
study involves collection of patient information, clinical data and test reports done as part of 
regular clinical care.  
I understand that my withdrawal from the study, at any time will not affect the treatment 
being given. 
Study Title: Natural history of multiple sclerosis in Indian prospective: Experience 
from a tertiary care hospital.  
Study Number: 
Subject‘s Initials: _________ Subject‘s Name: ________     Date of Birth / Age:_______ 
Please initial box  
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _______ for the 
above study and have had the opportunity to ask questions. [    ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [    ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor‘s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission  
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to look at my health records both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published. [    ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [    ] 
(v) I agree to take part in the above study. [     ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory‘s Name: _________________________________ 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
 
 
Sl. No Hosp No age Age@onset Gender MS Type Pre_time PS_visual PS_Motor PS_sensory PS_BG_Cer PS_sphinc Presentation Brain stem Cerebellar
1 398205C 17 8 1 1 2 3 2 2 2 2 1 2 2
2 627718C 56 36 2 2 3 3 2 2 2 1 2 2 2
3 050428B 60 35 1 1 2 3 1 2 2 2 1 2 2
4 474298D 34 26 2 1 2 3 5 2 2 2 1 2 1
5 724895D 27 25 1 1 1 3 6 1 2 2 1 2 2
6 728606A 53 38 2 1 1 3 1 2 2 2 1 2 2
7 773085D 32 26 2 3 4 1 6 2 2 2 1 2 1
8 755312D 30 24 2 3 5 2 2 1 2 2 2 1 1
9 976243D 52 44 1 3 5 3 6 2 1 2 1 2 2
10 897142D 24 21 2 1 1 3 6 2 2 2 1 2 2
11 066691F 41 39 2 1 4 3 6 1 2 2 1 2 1
12 371542C 39 30 2 1 1 2 6 2 2 2 1 2 2
13 269167D 47 40 2 1 4 3 6 1 2 2 1 2 1
14 281535D 41 33 1 3 5 3 2 2 1 2 2 1 1
15 076251F 38 34 1 3 5 2 2 2 1 2 2 1 1
16 325909C 39 24 1 2 3 3 4 2 1 2 2 2 2
17 755804D 23 21 1 2 3 3 2 1 1 2 2 2 2
18 191049D 25 20 2 1 4 3 6 2 1 2 1 1 1
19 498108D 23 14 2 3 5 3 1 2 2 2 1 2 2
20 449583D 48 43 1 1 4 3 2 2 2 2 1 2 2
21 885656A 70 46 1 1 4 1 6 2 2 2 1 2 1
22 878454B 37 24 1 3 5 3 6 2 1 2 2 1 1
23 100610F 16 14 1 1 1 3 6 1 2 2 1 2 2
24 735461B 53 38 2 4 6 3 2 2 1 2 2 1 1
25 943384B 32 18 2 3 5 3 2 1 2 2 2 2 2
26 641653D 20 18 1 1 4 2 6 2 2 2 1 2 2
27 460277D 53 50 2 1 1 3 6 2 1 2 1 2 1
28 461869D 49 31 2 3 5 1 6 2 2 2 1 2 1
29 384846D 23 13 1 3 5 3 1 2 2 2 1 2 1
30 418640C 27 15 2 3 5 3 6 1 2 2 1 2 2
31 966226C 55 48 2 1 4 3 6 1 2 2 1 1 1
32 441700D 53 33 1 3 5 1 2 2 1 2 2 1 1
33 466752C 35 26 1 3 4 3 6 2 1 2 1 1 1
34 394227C 60 52 2 1 1 3 6 1 1 2 2 1 1
35 187403D 52 44 2 3 7 3 2 1 2 2 2 1 1
36 941900D 46 38 2 1 4 3 6 1 2 2 1 2 2
37 292956D 22 16 2 1 1 1 6 2 2 2 1 2 2
38 597029B 50 36 1 1 2 3 5 1 1 2 2 2 1
39 101154F 28 25 2 1 4 1 6 2 2 2 1 2 2
40 761303A 15 13 2 3 7 3 4 1 2 1 2 1 1
Sl. No Hosp No age Age@onset Gender MS Type Pre_time PS_visual PS_Motor PS_sensory PS_BG_Cer PS_sphinc Presentation Brain stem Cerebellar
41 662799A 62 40 2 1 4 3 6 2 1 2 1 1 1
42 965128D 27 16 1 3 5 1 6 2 2 2 1 1 1
43 397878D 44 41 2 1 2 3 6 1 2 2 1 2 2
44 536739D 42 37 1 2 3 3 2 2 1 2 2 2 2
45 950310D 15 13 1 1 1 2 6 2 2 2 1 2 2
46 938523C 40 32 2 3 4 3 6 1 2 2 1 2 2
47 871636D 47 38 1 3 6 3 2 2 2 2 1 1 1
48 977976D 49 26 2 1 1 1 6 2 2 2 1 1 1
49 055444F 22 19 2 1 4 3 1 2 2 2 1 1 1
50 063366F 30 18 2 3 5 1 6 2 2 2 1 2 1
51 989263D 34 33 2 1 1 3 6 1 2 2 1 2 2
52 953216C 34 28 2 1 1 1 6 2 2 2 1 2 2
53 554003C 36 26 2 1 1 1 6 2 2 2 1 2 2
54 490732D 21 18 1 1 4 3 1 2 1 2 2 2 2
55 450675D 49 30 1 1 4 1 1 2 2 2 2 2 2
56 765896D 33 30 1 1 4 3 1 2 1 2 2 2 2
57 792916D 35 31 2 1 4 3 6 1 2 2 1 2 2
58 792677D 22 18 2 1 4 1 6 2 2 2 1 1 2
59 481813D 35 30 1 3 7 1 6 2 2 2 1 2 2
60 468912D 20 12 2 3 1 3 2 2 1 2 2 1 1
61 849471D 26 21 2 1 1 1 6 2 2 2 1 2 2
62 663658B 31 15 2 1 2 3 6 1 2 2 1 2 2
63 732423D 26 21 2 2 3 3 2 2 2 2 1 2 2
64 730679D 40 34 2 1 4 3 6 2 1 2 1 2 1
65 899657D 19 17 2 1 4 3 2 2 2 2 1 2 1
66 916243D 32 25 2 1 7 3 6 2 1 2 1 2 2
67 997494D 22 17 2 3 4 1 6 2 2 2 1 2 2
68 506633D 50 25 2 1 4 3 6 1 2 2 1 2 2
69 746232D 26 21 2 1 4 2 6 2 1 2 2 1 1
70 452498D 31 29 2 1 1 3 6 1 2 2 1 1 2
71 431844C 33 25 2 2 7 3 2 2 1 2 2 1 1
72 589416D 28 22 1 2 3 3 2 1 2 2 2 2 2
73 621833D 25 23 2 1 4 3 6 1 2 2 1 2 2
74 881952C 39 33 1 1 1 1 6 2 2 2 1 1 2
75 562468D 36 33 1 1 1 3 6 2 1 2 1 1 2
76 411960D 39 28 2 3 5 3 6 1 2 2 1 1 1
77 418170D 25 22 2 1 4 3 6 1 2 2 1 2 2
78 522939D 45 39 2 2 3 3 2 1 1 2 2 2 1
79 523191D 22 16 2 1 4 1 6 2 2 2 1 1 1
80 568976D 36 32 2 2 3 3 6 2 1 2 1 1 1
Sl. No Hosp No age Age@onset Gender MS Type Pre_time PS_visual PS_Motor PS_sensory PS_BG_Cer PS_sphinc Presentation Brain stem Cerebellar
81 503082D 42 38 2 1 7 3 6 2 1 2 1 1 2
82 509141D 33 29 1 1 4 3 2 2 2 2 1 2 2
83 413741C 47 41 2 1 4 3 5 2 1 2 2 1 2
84 916614C 52 35 2 3 7 1 6 2 2 2 1 2 2
85 384846D 23 14 1 3 5 3 1 2 2 2 1 2 2
86 320125D 28 24 2 1 1 3 6 1 2 2 1 2 2
87 261700D 32 23 2 3 5 1 6 2 1 2 2 1 1
88 203824D 26 19 2 1 1 3 6 2 1 2 1 1 1
89 205764D 36 23 1 1 4 1 6 2 2 2 1 2 2
90 076819D 45 39 2 2 3 3 1 2 2 2 1 2 2
91 062854D 35 22 2 3 4 1 6 2 2 2 1 2 2
92 448922C 44 22 1 3 5 3 1 2 2 2 1 2 1
93 708203C 31 20 1 1 4 3 1 2 2 2 1 2 2
94 656678C 32 25 1 1 4 3 5 2 2 2 1 2 2
95 642626C 42 34 1 1 4 3 1 2 2 2 1 2 2
96 635641C 41 34 2 1 4 1 6 2 2 2 1 1 2
97 554003C 36 26 2 1 4 1 6 2 2 2 1 2 2
98 733701C 46 26 1 3 5 1 6 2 2 2 1 2 2
99 735379C 46 34 2 2 3 3 2 2 1 2 2 2 1
100 784483C 31 23 1 1 4 3 6 2 2 1 1 2 2
101 877393C 53 45 1 3 7 3 6 2 1 2 1 1 2
102 749124C 42 35 1 1 4 3 6 1 2 2 1 2 2
103 762669C 31 14 2 3 5 3 2 2 2 2 1 2 2
104 695259D 32 26 1 1 4 3 2 2 1 2 2 2 1
105 030804D 67 58 1 1 4 3 2 2 2 1 2 2 1
106 091146D 41 34 1 2 7 3 5 1 1 2 2 1 1
107 136923D 27 20 2 3 5 3 6 2 1 2 1 2 2
108 214084D 27 23 1 1 1 3 2 1 1 2 2 1 2
109 224989D 44 33 1 3 5 3 6 2 2 1 1 2 2
110 298403D 37 29 2 1 1 1 6 2 2 2 1 2 2
111 669940B 44 40 2 1 4 3 6 1 2 2 1 2 2
112 054219C 35 24 2 1 4 3 2 2 2 2 1 2 2
113 572742D 43 36 1 3 5 3 2 1 2 2 2 2 2
114 223278D 34 19 2 3 5 1 6 2 1 2 2 1 1
115 632098D 33 28 1 3 5 3 6 2 1 2 2 1 1
116 297211C 41 32 1 3 5 3 2 2 2 2 1 2 2
117 332937D 54 49 1 2 3 3 2 2 2 1 2 2 2
118 209903C 45 42 1 1 4 1 6 2 2 2 1 2 2
119 917097B 34 28 1 1 1 3 6 2 1 2 1 1 2
120 246960D 60 44 1 3 7 3 6 1 2 2 1 2 2
Sl. No Hosp No age Age@onset Gender MS Type Pre_time PS_visual PS_Motor PS_sensory PS_BG_Cer PS_sphinc Presentation Brain stem Cerebellar
121 943183C 34 26 2 3 5 3 6 1 2 2 1 2 2
122 011525F 35 34 1 1 4 1 6 2 2 2 1 2 2
123 985114A 38 17 1 3 5 3 6 2 2 1 1 2 1
124 290373C 29 16 2 1 4 3 1 2 2 2 1 1 1
125 294271C 39 26 2 1 4 3 1 2 2 2 1 2 2
126 316974C 42 23 2 2 3 3 6 1 2 1 2 2 2
127 340576C 30 17 2 1 4 1 6 2 2 2 1 1 2
128 348050C 37 25 1 2 3 3 2 2 1 2 2 1 1
129 348809C 62 51 2 1 4 1 6 2 2 2 1 2 2
130 357767C 43 34 1 1 4 3 6 2 1 2 1 2 2
131 426229C 54 44 1 2 3 3 5 2 2 2 2 2 2
132 447246C 52 39 2 1 4 3 2 2 1 2 2 2 1
133 328997C 28 19 1 1 4 3 5 2 2 2 1 2 1
134 478490C 37 28 2 1 4 1 6 2 2 2 1 2 2
135 499143C 61 40 1 3 7 3 2 2 1 2 2 2 2
136 490488C 32 20 2 1 4 3 6 2 1 2 1 2 2
137 453146C 60 46 1 2 5 3 2 2 1 1 2 2 2
138 660068C 42 25 2 1 4 1 6 2 2 2 1 2 2
139 732030C 60 48 1 3 5 3 1 1 2 2 2 2 2
140 775066C 47 32 1 3 5 1 6 2 2 2 1 2 2
141 918561C 45 36 1 2 3 3 1 2 2 2 1 2 2
142 327322C 58 45 1 2 3 3 2 2 1 1 2 2 2
143 025532D 63 58 2 1 4 3 4 2 2 2 1 2 2
144 035794D 47 34 1 2 3 3 5 1 2 2 2 2 2
145 500939C 47 36 1 2 3 3 2 2 1 2 2 2 1
146 087137D 41 34 2 1 4 3 6 2 1 2 1 2 2
147 090929D 34 26 1 1 4 3 2 2 2 2 1 2 2
148 115887D 50 40 1 3 5 1 1 2 2 2 2 2 1
149 348210D 40 31 1 3 5 3 6 1 2 2 1 2 1
150 351764D 32 28 1 1 4 1 6 2 2 2 1 1 2
151 411306D 43 36 2 2 3 3 2 2 2 1 2 2 2
152 450423D 23 18 2 3 5 3 2 2 1 2 2 2 1
153 192491C 57 40 1 3 5 3 2 2 2 2 1 2 1
154 010771C 39 26 2 1 4 3 2 2 1 2 2 1 1
155 200679C 45 33 1 2 3 3 2 2 1 1 2 2 1
156 099031C 43 30 2 2 3 3 2 2 1 2 2 2 1
157 099436C 41 28 2 1 4 3 5 2 2 2 1 2 2
Sl. No Hemispheric Opticospin Myelitis OPTIC_NERVE DIPLOPIA NYSTAGMUS INO OPTHALM LHERMITTE UHTHOFF TRIGEMINAL_ NA Dysthesia/parasth
1 2 2 1 2 2 2 2 2 1 2 2 1
2 2 2 1 2 2 2 2 2 1 2 2 1
3 2 2 1 2 2 2 2 2 2 2 2 1
4 1 2 2 2 2 2 2 2 1 2 2 1
5 2 2 1 2 2 2 2 2 2 2 2 1
6 2 1 1 1 2 2 2 2 2 2 2 1
7 2 2 1 1 2 2 2 2 2 2 2 1
8 2 2 1 1 2 1 1 2 2 2 2 1
9 2 1 1 1 1 2 2 2 2 2 2 1
10 2 1 1 1 2 2 2 2 2 2 2 2
11 2 2 1 2 2 2 2 2 2 2 2 1
12 2 1 1 1 2 2 2 2 2 2 1 1
13 2 1 1 1 2 2 2 2 1 2 1 1
14 2 2 1 1 1 2 2 2 1 2 2 1
15 2 2 2 1 2 2 2 2 2 2 2 2
16 2 2 1 2 2 2 2 2 2 2 2 2
17 2 2 1 1 2 2 2 2 1 2 2 1
18 2 1 1 1 2 2 2 2 2 2 2 1
19 2 2 1 2 2 2 2 2 1 2 2 1
20 2 1 1 1 2 2 2 2 2 2 2 1
21 2 1 1 1 2 2 2 2 2 2 2 1
22 2 1 1 1 1 1 2 2 2 2 2 1
23 2 2 2 1 2 2 2 2 1 2 2 2
24 2 2 1 2 2 2 2 2 2 2 2 1
25 2 2 1 2 2 2 2 2 1 2 2 1
26 2 2 2 1 2 2 2 2 2 2 2 1
27 2 2 1 2 2 2 2 2 2 2 2 1
28 2 1 1 1 2 2 2 2 2 2 2 1
29 2 1 1 1 2 2 2 2 2 2 2 1
30 2 1 1 1 1 1 2 2 1 2 2 1
31 1 2 1 1 1 1 1 1 1 2 2 1
32 2 2 1 1 1 1 1 1 2 2 2 1
33 2 2 1 1 1 1 2 2 2 2 2 1
34 2 2 2 1 1 1 1 1 2 2 2 2
35 2 2 1 1 1 1 1 1 1 1 1 1
36 2 2 1 2 2 2 2 2 2 1 2 1
37 2 1 1 1 2 2 2 2 2 2 2 1
38 1 2 2 2 2 2 2 2 2 2 2 1
39 1 2 2 1 2 2 2 2 2 2 2 1
40 2 1 1 1 2 2 2 2 2 2 2 1
Sl. No Hemispheric Opticospin Myelitis OPTIC_NERVE DIPLOPIA NYSTAGMUS INO OPTHALM LHERMITTE UHTHOFF TRIGEMINAL_ NA Dysthesia/parasth
41 2 2 2 2 2 1 2 2 2 2 2 1
42 2 2 1 1 1 1 2 1 2 2 2 2
43 2 1 1 1 1 2 2 2 2 2 2 1
44 2 2 1 2 2 2 2 2 2 2 2 1
45 2 1 1 1 2 2 2 2 2 2 2 1
46 2 2 1 2 2 2 2 2 2 2 2 1
47 2 2 1 1 1 1 1 1 2 2 2 2
48 2 2 2 1 1 2 2 1 2 2 2 1
49 2 1 1 1 2 2 2 2 1 2 2 1
50 2 2 1 1 2 2 2 2 2 2 2 1
51 2 2 1 2 2 2 2 2 2 2 2 1
52 2 2 2 1 2 2 2 2 2 2 2 2
53 2 1 1 1 2 2 2 2 2 2 2 1
54 2 1 1 1 2 2 2 2 2 2 2 2
55 2 2 1 1 2 2 2 2 2 2 2 1
56 2 1 2 1 1 1 2 2 2 2 2 1
57 2 1 1 1 2 2 2 2 1 2 2 1
58 2 1 1 1 2 2 2 2 2 2 2 1
59 2 1 1 1 2 2 2 2 2 2 2 1
60 2 1 1 1 1 1 2 2 2 2 2 2
61 2 2 2 1 2 2 2 2 2 2 2 2
62 2 2 1 2 2 2 2 2 2 2 2 1
63 2 2 1 2 2 2 2 2 2 2 2 1
64 2 1 1 1 1 2 2 2 2 2 2 1
65 2 1 1 1 2 2 2 2 2 2 2 1
66 2 1 1 1 1 2 2 2 2 2 1 1
67 2 1 1 1 2 2 2 2 2 2 2 1
68 2 2 1 2 2 2 2 2 2 2 2 1
69 2 2 1 1 1 2 2 2 2 2 2 1
70 2 2 2 2 1 2 2 2 2 2 1 1
71 2 2 2 2 2 2 2 2 2 2 1 1
72 2 2 1 2 2 2 2 2 2 2 2 1
73 2 2 1 2 2 2 2 2 2 2 2 2
74 2 2 2 1 2 2 2 2 2 2 2 2
75 2 2 2 1 1 2 2 2 2 2 2 2
76 1 2 1 1 1 1 2 2 2 2 2 2
77 2 1 1 1 2 2 2 2 2 2 2 1
78 2 2 1 2 2 2 1 1 2 2 2 1
79 2 2 2 1 1 1 2 2 2 2 2 1
80 2 2 2 2 1 1 2 2 2 2 2 2
Sl. No Hemispheric Opticospin Myelitis OPTIC_NERVE DIPLOPIA NYSTAGMUS INO OPTHALM LHERMITTE UHTHOFF TRIGEMINAL_ NA Dysthesia/parasth
81 2 2 1 2 2 2 2 2 1 2 2 1
82 2 1 1 1 2 2 2 2 2 2 2 1
83 2 2 1 2 2 2 2 2 2 2 2 1
84 2 1 1 1 2 2 1 2 2 2 2 1
85 2 1 1 1 2 2 2 2 2 2 2 1
86 2 1 1 1 2 2 2 2 1 2 2 1
87 2 2 1 1 1 1 2 1 2 2 2 1
88 2 2 2 1 1 1 2 1 2 2 2 2
89 2 2 2 1 2 2 2 2 2 2 2 2
90 2 2 1 2 2 2 2 2 2 2 2 2
91 2 1 1 1 2 2 2 2 2 2 2 2
92 2 2 1 2 2 1 2 2 2 2 2 1
93 2 2 1 2 2 2 2 2 2 2 2 2
94 2 2 1 2 2 2 2 2 1 2 2 1
95 2 1 1 2 1 1 2 2 2 2 2 1
96 2 1 1 1 1 2 2 2 2 2 2 1
97 2 1 1 1 2 2 2 2 2 2 2 2
98 2 1 1 1 2 2 2 2 2 2 2 2
99 2 2 1 1 2 1 2 2 2 2 2 2
100 2 1 1 1 2 2 2 2 1 2 2 2
101 2 1 1 1 1 2 2 2 2 2 2 1
102 2 2 1 2 2 2 2 2 2 2 2 1
103 2 1 1 1 2 2 2 2 1 2 2 1
104 2 1 1 1 1 2 2 2 2 1 2 1
105 2 2 2 2 2 2 2 2 2 2 2 2
106 1 2 2 1 1 2 2 2 2 2 2 1
107 2 1 1 1 1 2 2 2 2 2 2 1
108 2 2 2 2 2 2 2 2 2 2 1 1
109 2 1 1 1 2 1 2 2 2 2 2 2
110 2 1 1 1 2 2 2 2 2 2 1 1
111 2 2 1 2 2 2 2 2 2 2 2 1
112 2 1 1 1 1 2 2 2 2 2 2 1
113 2 2 1 2 2 2 2 2 2 2 2 1
114 2 2 1 1 1 1 2 2 2 2 2 1
115 2 2 1 2 1 1 2 2 2 2 2 2
116 2 2 1 2 2 2 2 2 2 1 2 1
117 1 2 1 2 2 2 2 2 2 2 2 1
118 2 1 1 1 2 2 2 2 1 2 2 1
119 2 2 2 2 2 2 2 2 2 2 2 1
120 2 2 1 2 2 2 2 2 1 2 2 1
Sl. No Hemispheric Opticospin Myelitis OPTIC_NERVE DIPLOPIA NYSTAGMUS INO OPTHALM LHERMITTE UHTHOFF TRIGEMINAL_ NA Dysthesia/parasth
121 2 2 1 2 2 2 2 2 2 2 2 1
122 1 2 2 1 2 2 2 2 2 2 2 1
123 2 1 1 1 2 2 2 2 1 2 2 1
124 2 2 1 1 2 2 2 2 2 2 2 1
125 2 2 1 2 2 2 2 2 2 2 2 1
126 2 2 1 2 2 2 2 2 2 2 2 1
127 2 1 1 1 1 1 2 1 2 2 2 1
128 2 2 1 2 1 1 2 1 2 2 2 2
129 2 1 1 1 2 2 2 2 2 2 2 2
130 2 1 1 1 1 2 2 2 2 2 2 2
131 1 2 2 2 2 2 2 2 2 2 2 2
132 2 2 2 2 2 2 2 2 2 2 2 2
133 1 2 2 2 2 2 2 2 2 2 2 2
134 1 2 1 1 2 2 2 2 2 2 2 2
135 2 2 1 2 2 2 2 2 2 2 2 2
136 2 1 1 1 1 1 2 2 1 2 2 1
137 2 2 1 2 2 2 2 2 2 2 2 2
138 2 1 1 1 2 2 2 2 2 2 2 2
139 2 2 1 2 2 2 2 2 2 2 2 1
140 2 1 1 1 2 2 2 2 2 2 2 1
141 2 2 1 2 2 2 2 2 2 1 2 2
142 2 2 1 2 2 1 2 2 2 2 2 2
143 2 2 1 2 2 2 2 2 2 2 2 1
144 2 2 1 2 2 2 2 2 2 2 2 1
145 2 2 1 2 2 2 2 2 2 2 2 2
146 2 1 1 1 1 1 2 2 2 2 2 2
147 2 2 1 2 2 2 2 2 2 2 2 1
148 2 1 1 1 2 2 2 2 2 2 2 2
149 2 1 1 1 2 1 2 2 2 2 2 2
150 2 1 1 1 1 1 2 2 2 2 2 2
151 2 2 1 2 2 2 2 2 2 2 2 2
152 2 2 1 2 2 2 2 2 2 2 2 2
153 2 2 1 2 2 2 2 2 1 2 2 1
154 2 1 1 1 1 1 2 2 2 2 2 1
155 2 2 1 2 2 1 1 1 2 2 2 2
156 2 2 2 2 2 1 2 2 2 2 2 2
157 1 2 1 2 2 2 2 2 2 2 2 2
Sl. No B_UMN LMN CONSTIPATION INCONTINENCE SEXUAL_ DYS FATIGUE GAIT_INV LIMB_ATAXIA VERTIGO SEIZURES Pyramidal Total Epis EDSS@Pre
1 2 2 2 2 2 2 1 2 2 1 1 6 6.5
2 1 1 1 2 2 1 1 2 2 2 1 1 8
3 2 2 2 2 2 2 1 2 2 2 1 5 4.5
4 1 2 1 2 2 2 1 1 1 2 1 2 2
5 2 2 2 2 2 2 2 2 2 2 1 2 1
6 2 2 2 2 2 2 1 2 2 2 2 3 4
7 1 1 1 2 2 1 1 2 2 2 1 6 4
8 1 2 1 1 2 1 1 1 2 1 1 4 6.5
9 1 1 1 2 1 1 1 2 2 2 1 4 4
10 2 2 2 2 2 2 1 2 2 2 1 4 2.5
11 1 2 2 2 2 1 2 2 1 2 1 3 2.5
12 2 2 2 2 2 2 1 1 2 2 1 4 7
13 1 1 2 2 2 1 2 2 2 2 1 2 2.5
14 1 1 1 2 1 1 2 1 2 2 1 3 6.5
15 1 2 2 2 1 2 1 1 1 2 2 3 6.5
16 1 2 2 1 1 2 1 2 2 1 1 1 4
17 1 1 1 2 1 2 1 2 2 2 1 1 5
18 1 2 2 2 2 1 1 1 2 2 1 2 5
19 1 1 1 2 2 1 1 2 2 2 1 3 4.5
20 1 2 1 2 2 1 1 2 2 2 1 3 3
21 1 1 1 2 2 2 1 2 2 2 1 4 5.5
22 1 1 1 1 2 1 1 1 2 2 1 4 4
23 2 2 2 2 2 2 2 2 2 2 2 2 1
24 1 1 1 2 2 1 1 1 2 2 1 1 5
25 1 2 1 2 2 2 1 2 2 2 1 3 4
26 2 2 2 2 2 1 2 2 2 2 2 2 3
27 2 2 2 2 2 1 1 2 2 2 2 2 3
28 1 1 2 2 2 1 1 2 2 1 1 3 5
29 1 1 1 2 1 1 1 2 2 2 1 4 5
30 1 1 1 2 2 1 1 2 2 2 1 4 4.5
31 1 1 2 2 2 1 1 1 1 2 1 4 4
32 1 1 1 2 2 1 1 1 1 1 1 3 5
33 1 1 1 2 1 1 1 2 1 2 1 3 4
34 1 2 2 2 2 2 1 2 1 2 2 2 3
35 1 1 1 2 2 1 1 2 1 2 1 3 4
36 2 2 2 2 2 1 1 2 2 2 1 3 1.5
37 2 2 2 2 2 2 2 2 2 2 1 4 2
38 2 2 2 2 2 1 1 1 2 2 1 1 5
39 2 2 2 2 2 2 2 2 1 2 1 2 5
40 1 1 1 2 2 2 1 1 1 2 1 3 7
Sl. No B_UMN LMN CONSTIPATION INCONTINENCE SEXUAL_ DYS FATIGUE GAIT_INV LIMB_ATAXIA VERTIGO SEIZURES Pyramidal Total Epis EDSS@Pre
41 1 2 1 2 2 1 1 2 1 2 1 3 5
42 1 1 1 2 1 1 1 1 2 2 1 3 6.5
43 1 1 1 2 2 1 1 2 1 2 1 2 3
44 1 1 1 2 1 1 1 2 1 2 1 1 4.5
45 1 1 1 2 2 2 2 2 2 2 1 2 4.5
46 1 1 1 2 2 1 1 2 2 2 1 4 4
47 1 2 1 2 1 2 1 1 1 2 1 3 5
48 2 2 2 2 2 2 2 2 1 2 2 5 2
49 1 1 1 2 2 1 1 1 1 2 1 5 5
50 1 1 1 2 2 2 1 1 1 2 1 4 5
51 1 2 1 2 2 2 2 2 2 2 1 1 2.5
52 2 2 2 2 2 2 2 2 2 2 2 1 2
53 2 2 2 2 2 1 1 2 2 1 1 2 3.5
54 2 2 2 2 1 1 1 2 2 2 1 3 2.5
55 1 1 1 2 2 1 1 2 2 2 1 4 4.5
56 1 2 2 2 2 2 1 1 1 2 1 3 5.5
57 1 2 2 2 2 1 1 1 2 2 1 3 3
58 2 2 2 2 2 1 2 2 1 2 1 3 3
59 1 1 1 2 1 1 1 2 2 2 1 2 6
60 2 2 2 2 2 1 1 1 2 2 1 3 4.5
61 2 2 2 2 2 1 2 2 1 2 2 3 2.5
62 2 2 2 2 2 2 1 2 2 2 2 9 4
63 1 2 2 2 2 2 1 2 2 2 1 1 5
64 1 2 2 2 2 1 1 1 2 1 1 3 5
65 1 2 2 2 2 1 1 2 2 2 1 2 4.5
66 2 2 2 2 2 2 1 2 2 2 1 6 3
67 1 2 1 1 2 1 1 2 2 2 1 4 5.5
68 2 2 2 2 2 2 1 2 2 2 1 2 3.5
69 2 2 2 2 2 2 1 1 1 2 1 4 4.5
70 2 2 2 2 2 2 2 2 2 2 2 2 2.5
71 1 2 1 2 2 1 1 1 1 2 1 1 5
72 2 1 2 2 2 1 1 2 2 2 1 1 4.5
73 1 1 2 2 2 1 1 2 2 2 1 2 4.5
74 2 2 2 2 2 2 2 2 2 2 2 2 2.5
75 2 2 2 2 2 2 2 2 2 2 2 1 2
76 1 1 1 2 2 1 1 1 2 2 1 5 6
77 1 1 1 2 2 1 1 2 2 2 2 2 3.5
78 1 1 1 2 2 1 1 1 2 2 1 1 6
79 1 2 2 2 2 1 1 2 1 2 2 3 4
80 2 2 2 2 2 1 1 1 2 2 2 1 4.5
Sl. No B_UMN LMN CONSTIPATION INCONTINENCE SEXUAL_ DYS FATIGUE GAIT_INV LIMB_ATAXIA VERTIGO SEIZURES Pyramidal Total Epis EDSS@Pre
81 1 1 1 2 2 1 1 2 1 2 1 3 4
82 1 1 1 2 2 1 1 2 2 2 1 3 4.5
83 1 1 1 2 2 1 1 2 1 2 1 3 4.5
84 1 2 2 2 2 1 1 2 2 2 1 5 5
85 1 1 1 2 2 1 1 2 2 2 1 4 4
86 1 2 2 2 2 1 1 2 2 2 1 3 3
87 1 1 2 2 2 1 1 1 2 2 1 4 6.5
88 2 2 2 2 2 1 2 2 1 2 1 2 4
89 1 2 2 2 2 2 1 2 2 2 1 3 4.5
90 1 2 2 2 2 2 1 2 2 2 1 1 5
91 1 1 1 2 2 1 1 2 2 2 1 2 4
92 2 2 2 2 2 1 1 1 2 2 1 5 4
93 1 1 1 2 1 1 1 2 2 2 1 4 5
94 2 2 2 2 2 1 1 2 2 2 1 2 4
95 1 1 1 2 2 1 1 2 2 2 1 3 6
96 1 2 2 2 2 1 1 2 2 2 1 4 5
97 1 2 2 2 2 2 1 2 2 2 1 2 5
98 1 1 1 1 2 1 1 2 2 2 1 5 5
99 2 2 2 2 2 1 1 1 2 2 1 1 4.5
100 1 1 1 2 1 1 1 2 2 2 1 5 5
101 1 1 1 2 2 1 1 2 2 2 1 3 3
102 2 2 2 2 2 1 1 2 2 2 1 3 4
103 1 1 1 1 2 1 1 2 2 2 1 5 5
104 2 2 2 2 2 1 1 1 1 2 1 4 4
105 1 1 1 1 2 1 1 1 2 2 1 3 5
106 2 2 2 2 2 2 1 1 2 2 1 1 5
107 1 1 1 1 2 1 1 2 1 2 1 3 6
108 2 2 2 2 2 1 1 2 1 2 1 2 3.5
109 1 1 2 2 2 1 1 2 2 2 1 3 4
110 2 2 2 2 2 2 2 2 1 2 1 4 3.5
111 2 2 2 2 2 1 1 2 2 2 1 2 4
112 1 1 1 2 2 1 1 2 2 2 1 3 6
113 1 1 1 2 1 2 1 2 2 2 1 2 8
114 1 1 1 2 2 1 1 1 1 2 1 5 6
115 1 2 1 2 1 1 1 1 2 2 1 3 4
116 1 1 1 2 1 1 1 2 2 2 1 3 4
117 1 2 1 2 1 1 1 2 2 2 1 1 4.5
118 2 2 2 2 2 2 2 2 2 2 1 3 3
119 2 2 2 2 2 1 1 2 2 2 1 2 3.5
120 2 2 1 2 1 1 1 2 2 2 1 2 8
Sl. No B_UMN LMN CONSTIPATION INCONTINENCE SEXUAL_ DYS FATIGUE GAIT_INV LIMB_ATAXIA VERTIGO SEIZURES Pyramidal Total Epis EDSS@Pre
121 1 1 1 2 2 1 1 2 2 2 1 5 5
122 2 2 2 2 2 1 1 2 2 2 1 2 4
123 1 2 2 2 1 1 1 1 2 2 2 7 6
124 2 2 2 2 2 2 1 1 1 2 1 4 4.5
125 1 1 1 1 2 1 1 2 2 2 1 1 7
126 1 1 1 1 2 1 1 2 2 2 1 1 6.5
127 1 1 2 2 2 1 1 2 1 2 1 4 5
128 2 2 2 2 2 1 1 1 1 1 1 1 6
129 2 2 2 2 2 1 1 2 2 2 1 3 4
130 2 2 2 2 2 2 1 2 2 2 1 2 4
131 2 2 1 2 2 2 1 2 2 2 1 1 4.5
132 2 2 2 2 2 2 1 1 2 2 1 12 4
133 2 2 2 2 2 2 1 1 2 2 1 3 4.5
134 2 2 2 2 2 2 2 2 2 2 1 3 3
135 1 1 1 2 2 1 1 2 2 1 1 3 6.5
136 1 1 1 2 2 1 1 2 2 2 1 2 4
137 1 1 1 2 2 2 1 2 2 2 1 1 4.5
138 2 2 2 2 2 2 1 2 2 2 1 3 4
139 2 2 2 2 2 2 1 2 2 2 1 2 4.5
140 1 1 1 1 2 2 1 2 2 2 1 3 5
141 2 2 2 2 2 2 1 2 2 2 1 1 4
142 1 1 1 2 1 1 1 2 2 2 1 1 5
143 1 1 1 2 2 2 1 2 2 2 2 3 8
144 2 2 2 2 2 2 1 2 2 2 1 1 4.5
145 1 1 1 1 1 1 1 1 2 2 1 1 5.5
146 1 1 1 2 2 1 1 2 2 2 1 3 4.5
147 1 2 2 2 2 1 1 2 2 2 1 3 4
148 2 1 1 2 1 1 1 1 2 2 1 5 4.5
149 2 2 2 2 2 1 1 1 2 2 1 3 6
150 2 2 2 2 2 2 1 2 2 2 1 5 4
151 1 1 1 2 2 1 1 2 2 2 1 1 4.5
152 1 1 1 2 2 2 1 1 2 2 1 3 4
153 1 1 1 2 2 1 1 2 2 2 1 3 4.5
154 1 1 2 2 2 2 1 1 2 2 2 4 4.5
155 1 1 1 2 1 1 1 1 2 2 1 2 4.5
156 1 2 2 2 2 1 1 1 2 2 2 1 5
157 2 2 2 2 2 2 1 2 2 2 2 2 4.5
Sl. No EDSS@Pres CSF_PROTEIN CSF_PROTEIN CELLS OCB VEP BAEP SSEP_MEDIAN SSEP_TIBIAL MRI_LESIONS JUXTRACORTICAL PERIVENTRICULAR Sl. No
1 2.5 2 1 1 2 1 1 1 1 2 2 1 1
2 7 4 1 1 2 3 1 1 2 4 1 1 2
3 1 1 1 2 3 1 1 2 2 4 1 1 3
4 2 1 1 1 1 1 3 3 1 4 1 1 4
5 1 1 1 1 1 2 3 1 1 4 1 1 5
6 1 1 1 2 2 5 5 5 5 4 1 1 6
7 4.5 3 1 1 2 3 1 2 2 4 1 1 7
8 5.5 3 1 2 2 3 3 2 2 4 1 1 8
9 4 2 2 1 2 2 3 3 2 4 1 1 9
10 1.5 1 2 3 1 3 1 2 2 4 1 1 10
11 2.5 2 1 2 1 1 3 1 2 2 2 1 11
12 2.5 2 2 1 2 1 3 1 1 1 2 1 12
13 2.5 2 2 1 2 1 3 1 1 2 2 1 13
14 7 4 2 1 3 1 3 3 1 4 2 2 14
15 7 4 1 1 2 3 3 3 2 4 1 1 15
16 6 2 1 1 3 1 3 3 4 1 1 16
17 4 2 2 1 1 3 3 3 1 4 1 1 17
18 1 1 1 1 2 3 2 3 2 4 1 1 18
19 3.5 2 1 1 1 1 3 3 2 4 2 1 19
20 2.5 2 2 1 2 3 3 3 2 2 1 1 20
21 4 2 1 1 3 2 1 2 2 2 1 1 21
22 5.5 3 2 3 3 3 3 3 3 4 1 1 22
23 1 1 1 2 2 3 1 1 1 2 1 1 23
24 8 4 1 1 2 3 1 2 2 4 1 1 24
25 3 2 1 1 3 1 2 2 2 4 1 1 25
26 1 1 1 3 1 3 1 1 2 4 1 1 26
27 1 1 2 1 2 3 3 3 2 4 1 1 27
28 4 2 2 1 2 3 3 3 2 4 1 1 28
29 3 2 1 1 2 3 3 3 2 4 1 1 29
30 8 4 1 1 1 3 2 2 2 4 1 1 30
31 3 2 1 1 2 3 2 3 2 4 1 1 31
32 5 3 2 1 2 3 2 1 2 4 1 1 32
33 4.5 3 2 1 2 3 2 3 2 4 1 1 33
34 2.5 2 1 1 2 2 1 1 1 4 1 1 34
35 6.5 4 1 1 2 1 3 1 2 4 2 2 35
36 1.5 1 2 2 2 1 3 1 2 4 1 1 36
37 1 1 1 3 1 3 3 1 1 4 1 1 37
38 2 1 2 1 3 3 1 3 1 1 2 2 38
39 4 2 1 1 2 2 3 2 2 1 1 2 39
40 10 5 1 1 3 3 3 2 2 4 1 1 40
Sl. No EDSS@Pres CSF_PROTEIN CSF_PROTEIN CELLS OCB VEP BAEP SSEP_MEDIAN SSEP_TIBIAL MRI_LESIONS JUXTRACORTICAL PERIVENTRICULAR Sl. No
41 3 2 2 1 2 1 1 1 1 4 1 1 41
42 6.5 4 1 3 2 3 3 2 2 4 1 1 42
43 2.5 2 1 1 1 1 1 3 1 4 1 1 43
44 5.5 3 1 1 3 1 3 2 2 4 1 1 44
45 3 2 1 1 2 3 3 3 2 1 1 2 45
46 6.5 4 1 1 1 3 1 2 2 4 1 1 46
47 6 4 1 2 2 3 3 2 2 4 1 1 47
48 2 1 1 1 1 3 1 1 1 4 1 1 48
49 4 2 2 1 2 3 1 1 2 4 2 2 49
50 4.5 3 2 1 2 3 3 2 2 4 1 1 50
51 2 1 1 1 2 1 3 2 1 4 1 1 51
52 1 1 1 1 2 2 1 1 1 1 1 1 52
53 3 2 1 1 2 2 1 2 2 4 1 1 53
54 2 1 1 1 2 3 3 3 3 4 1 1 54
55 4 2 1 1 1 3 1 2 2 4 1 1 55
56 4 2 2 2 2 3 3 3 2 4 1 1 56
57 3 2 1 1 2 1 3 3 1 1 2 2 57
58 10 5 1 1 1 3 3 1 2 4 1 1 58
59 8 4 2 1 2 1 3 1 2 4 1 1 59
60 3 2 1 1 1 3 2 2 2 4 1 1 60
61 2 1 2 1 1 2 3 1 1 4 1 1 61
62 2 1 1 1 1 3 1 1 2 4 1 1 62
63 5.5 3 1 1 2 2 3 3 2 4 1 1 63
64 3 2 1 1 1 3 1 3 2 4 1 1 64
65 3 2 2 1 2 3 3 2 2 4 1 1 65
66 2.5 2 1 2 2 3 3 3 2 4 1 1 66
67 6 1 1 2 3 3 1 3 4 1 1 67
68 1 1 1 1 2 2 3 1 1 4 1 1 68
69 3 2 1 1 1 3 3 3 3 4 1 1 69
70 2 1 1 2 2 3 3 1 2 4 1 1 70
71 6 1 1 1 1 1 1 1 4 1 1 71
72 5.5 3 2 2 3 3 3 2 2 4 1 1 72
73 3 2 1 2 2 4 3 3 3 4 1 1 73
74 1 1 2 2 2 3 2 2 2 4 1 1 74
75 0 1 1 2 1 2 3 3 1 2 1 1 75
76 5 3 1 1 2 3 3 3 2 4 1 1 76
77 2 1 1 1 2 2 3 3 1 4 1 1 77
78 6.5 4 1 1 2 3 3 2 2 4 1 1 78
79 2.5 2 1 1 2 3 2 1 2 4 1 1 79
80 5 3 1 1 1 3 3 3 1 4 1 1 80
Sl. No EDSS@Pres CSF_PROTEIN CSF_PROTEIN CELLS OCB VEP BAEP SSEP_MEDIAN SSEP_TIBIAL MRI_LESIONS JUXTRACORTICAL PERIVENTRICULAR Sl. No
81 2.5 2 1 2 2 1 2 1 1 4 1 1 81
82 3 2 2 1 2 3 3 2 2 4 1 1 82
83 6 1 1 2 2 3 2 2 4 1 1 83
84 6.5 4 1 1 1 4 3 3 3 4 1 1 84
85 3 2 1 1 1 3 2 3 2 4 1 1 85
86 2 1 1 1 2 3 3 3 1 4 1 1 86
87 7 4 2 1 1 3 3 2 2 4 1 1 87
88 1 1 2 1 2 2 3 3 2 4 1 1 88
89 4 2 1 1 2 2 3 1 1 4 1 1 89
90 6 2 1 1 3 3 3 2 4 1 1 90
91 5 3 1 1 1 3 1 2 3 4 1 1 91
92 5.5 3 1 1 1 3 1 2 2 4 1 1 92
93 4 2 1 1 1 3 3 2 2 4 1 1 93
94 6 1 2 1 1 1 1 1 2 1 1 94
95 6 2 1 2 3 3 3 3 4 1 1 95
96 4 2 2 2 2 1 1 2 2 4 1 1 96
97 6 1 1 1 2 2 3 2 4 1 1 97
98 6 1 2 1 3 2 2 2 4 1 1 98
99 6 1 1 2 3 2 1 3 4 1 1 99
100 6 1 1 2 2 1 1 1 4 1 1 100
101 4 2 2 2 2 3 3 3 2 3 1 1 101
102 6 1 1 2 1 1 3 1 4 1 1 102
103 6 2 2 1 3 2 1 1 4 1 1 103
104 3 2 1 2 2 3 2 2 2 4 1 1 104
105 7 4 2 1 2 3 2 2 2 4 1 1 105
106 7 4 2 1 2 1 1 1 1 4 1 1 106
107 8 4 1 1 2 3 1 2 1 4 1 1 107
108 6 1 1 2 1 3 1 1 4 1 1 108
109 6 1 1 2 2 3 1 3 4 1 1 109
110 5 3 1 1 1 2 3 2 2 4 1 1 110
111 1 1 1 1 2 1 3 3 2 4 1 1 111
112 6 1 1 1 3 3 3 2 4 1 1 112
113 6 2 1 1 2 3 3 2 4 1 1 113
114 7 4 2 1 2 3 1 2 2 4 1 1 114
115 6 4 1 2 2 1 3 1 2 4 1 1 115
116 6 1 1 2 3 3 1 1 4 1 1 116
117 5.5 3 1 1 2 1 1 3 1 4 1 1 117
118 1 1 1 1 2 3 3 3 1 4 1 1 118
119 6 2 2 1 2 3 3 2 4 1 1 119
120 6 2 1 1 1 1 2 2 4 1 1 120
Sl. No EDSS@Pres CSF_PROTEIN CSF_PROTEIN CELLS OCB VEP BAEP SSEP_MEDIAN SSEP_TIBIAL MRI_LESIONS JUXTRACORTICAL PERIVENTRICULAR Sl. No
121 7 4 1 1 1 1 2 3 1 4 1 1 121
122 2 1 2 1 2 2 3 1 1 2 1 1 122
123 6 2 1 2 2 3 2 2 4 1 1 123
124 6 1 1 2 2 1 1 2 4 1 1 124
125 6 1 1 2 5 5 5 5 4 1 1 125
126 7 4 1 2 2 3 3 2 2 4 1 1 126
127 6 1 1 1 3 2 3 2 4 1 1 127
128 6 1 1 1 3 2 2 2 4 1 1 128
129 6 1 1 1 2 3 3 2 4 1 1 129
130 6 1 1 1 1 1 1 1 2 1 1 130
131 6 2 1 2 3 1 1 2 4 1 1 131
132 6 1 1 1 2 3 1 2 4 1 1 132
133 6 1 2 1 5 5 5 5 4 1 1 133
134 6 1 1 2 3 3 2 1 4 1 1 134
135 6 1 1 2 3 3 3 3 4 1 1 135
136 6 1 1 1 3 2 2 1 4 1 1 136
137 6 2 1 3 3 3 3 3 4 1 1 137
138 5.5 3 1 1 1 3 1 3 3 4 1 1 138
139 6 2 1 1 3 2 3 2 4 1 1 139
140 8 4 1 2 2 2 1 2 2 4 1 1 140
141 6 1 1 2 5 5 5 5 4 1 1 141
142 6 2 1 2 3 2 2 2 4 1 1 142
143 5 3 1 1 2 1 1 1 1 4 1 1 143
144 6.5 4 1 1 2 1 1 1 2 4 1 1 144
145 6 1 1 1 3 2 2 2 4 1 1 145
146 2 1 1 1 2 2 3 1 1 4 1 1 146
147 7 4 1 2 1 3 2 2 2 4 1 1 147
148 7 4 1 1 1 3 3 2 2 4 1 1 148
149 8.5 5 1 1 1 3 3 3 2 4 1 1 149
150 5 3 1 1 2 1 1 1 1 4 1 1 150
151 6 2 1 2 3 3 3 2 4 1 1 151
152 7 4 1 1 2 3 3 3 2 4 1 1 152
153 8 4 1 1 2 3 3 3 2 4 1 1 153
154 6 1 2 2 3 2 2 2 4 1 1 154
155 6 2 2 3 3 2 3 2 4 1 1 155
156 6 2 3 2 3 3 3 1 4 1 1 156
157 6 1 1 2 5 5 5 5 4 1 1 157
INFRATENTORIAL CC DAWSON_F Ce BRAIN STEM BG THALAMUS SIZE_LES GADO CERVICAL Cerebral atrophy type F/U MRI after Improvement Atrophy
2 2 2 2 2 2 2 1 1 1 4 8 2 2
2 2 2 2 2 2 2 1 2 1 5 7 3 1
1 2 2 2 2 2 2 1 2 1 2 11 1 1
1 1 2 2 1 2 2 1 2 1 4 3 3 2
1 1 2 1 1 2 2 1 1 1 4 3 1 2
1 1 2 2 1 2 2 1 1 1 4 7 2 2
1 1 2 1 1 2 2 1 2 1 2 3 2 1
1 1 2 1 1 2 2 1 1 1 5 3 3 1
2 1 1 2 2 2 2 1 2 2 2 3 3 1
2 1 2 2 2 2 2 1 1 1 4 2 3 2
1 1 2 2 1 2 2 1 2 2 4 0 0 2
1 2 2 2 1 2 2 1 2 1 4 9 1 2
2 1 2 2 2 2 2 1 2 2 4 2 3 2
1 2 2 1 1 2 2 1 1 1 2 3 1 1
1 2 2 2 1 2 2 1 2 2 2 1 3 1
1 1 2 2 1 2 2 1 2 1 5 1 3 1
1 1 2 2 1 2 2 1 1 1 2 3 2 1
1 1 1 2 1 2 1 1 1 1 4 4 1 2
1 1 1 2 1 2 2 1 1 1 4 0.4 3 2
2 2 2 2 2 2 2 1 2 2 4 0 0 2
1 2 2 2 1 2 2 1 1 2 4 0 0 2
1 1 2 2 1 2 1 1 2 1 4 0 0 2
2 1 1 2 2 2 2 1 1 2 4 0.5 1 2
1 1 1 1 1 1 1 1 1 1 5 9 2 1
2 1 2 2 2 2 2 1 2 1 4 0 0 2
1 1 1 2 1 2 2 1 2 1 4 0.4 3 2
1 1 2 2 1 2 2 1 1 1 4 2 3 2
1 1 2 2 1 2 2 1 2 1 4 1 3 2
2 1 2 2 2 2 2 1 1 1 2 2 3 1
1 1 2 1 1 2 2 1 1 1 4 0.5 1 2
2 1 1 2 2 2 2 1 2 1 4 3 2 2
1 1 2 2 2 2 2 1 2 1 5 2 2 1
1 1 2 1 1 2 2 1 2 1 2 6 2 1
1 2 2 2 1 2 2 1 2 2 4 0 0 2
2 2 2 2 1 2 2 1 1 1 2 2 2 1
2 2 2 2 2 2 2 1 2 1 2 1 2 1
1 1 1 1 1 2 2 1 1 1 4 3 1 2
2 2 2 2 2 2 2 2 1 2 2 5 1 1
2 2 2 2 2 2 1 3 1 1 4 0.5 3 2
1 1 2 2 1 2 2 1 2 1 2 0 0 1
INFRATENTORIAL CC DAWSON_F Ce BRAIN STEM BG THALAMUS SIZE_LES GADO CERVICAL Cerebral atrophy type F/U MRI after Improvement Atrophy
1 1 2 1 1 2 2 1 1 2 2 2 1 1
1 1 2 1 1 2 2 1 2 1 5 0 0 1
1 1 2 2 1 2 2 1 1 1 4 2 3 2
2 1 2 2 2 2 2 1 2 1 4 2 3 2
2 2 2 2 2 2 2 1 2 2 2 0 0 1
1 1 1 2 2 2 2 1 1 1 2 4 2 1
1 1 2 2 2 2 2 1 2 1 5 1 2 1
1 1 1 2 2 2 2 1 2 1 2 1 1 1
2 2 2 2 1 2 2 1 1 1 2 0.5 2 1
1 1 1 1 1 2 2 1 2 1 5 0 1 1
1 1 1 2 1 2 2 1 1 1 4 0.4 1 2
2 1 2 2 2 2 2 1 1 1 4 6 1 2
2 1 2 2 2 2 2 1 2 1 4 4 3 2
1 1 2 2 1 2 2 1 1 1 4 0 0 2
1 1 2 2 1 2 2 1 2 1 4 1 3 2
1 2 2 1 1 2 2 1 2 2 4 1 1 2
2 2 2 2 2 2 2 1 2 1 4 1 3 2
2 1 1 2 2 2 2 1 2 1 4 0 0 2
2 2 2 2 2 2 2 1 2 1 2 0 0 1
1 2 2 1 1 2 1 1 1 1 2 1 2 1
2 1 2 2 2 2 2 1 1 1 4 1 3 2
1 1 1 2 1 2 2 1 1 1 2 13 2 1
1 1 2 2 1 2 2 1 2 1 4 0 0 2
1 2 2 2 1 2 2 1 2 1 2 0.5 2 1
1 1 1 1 1 2 2 1 1 1 5 1 2 1
2 1 2 2 1 2 2 1 2 1 4 0.3 3 2
1 2 2 2 1 2 2 1 2 1 4 1 2 2
1 1 1 2 1 2 2 1 1 1 4 3 3 2
1 1 1 2 1 2 2 1 1 1 4 0 0 2
1 2 2 1 1 2 2 1 2 1 2 3 2 1
1 1 1 1 1 1 2 1 2 1 2 5 1 1
1 2 2 2 1 2 2 1 2 1 2 3 2 1
1 1 1 2 1 2 2 1 2 1 4 0 0 2
1 1 1 2 1 2 2 1 2 1 2 5 3 1
2 2 2 2 2 2 2 1 2 1 4 0 0 2
1 1 1 1 1 1 1 1 2 1 5 2 2 1
1 1 2 2 1 2 2 1 2 1 2 3 1 1
1 1 1 1 1 2 2 1 2 1 2 1 3 1
1 1 1 2 1 2 2 1 2 1 4 0.5 1 2
1 1 2 2 1 2 2 1 2 1 5 2 1 1
INFRATENTORIAL CC DAWSON_F Ce BRAIN STEM BG THALAMUS SIZE_LES GADO CERVICAL Cerebral atrophy type F/U MRI after Improvement Atrophy
2 1 1 2 2 2 2 1 2 2 4 2 3 2
2 2 2 2 1 2 2 1 2 1 4 0.2 0 2
1 1 2 1 1 1 1 1 1 1 2 0 0 1
1 1 1 1 1 2 2 1 2 1 2 1 0 1
1 2 2 1 1 2 2 1 1 1 2 2 3 1
2 2 2 2 2 2 2 1 1 1 4 0 0 2
1 1 2 1 1 1 2 1 2 1 2 1 1 1
1 1 2 1 1 2 1 1 1 1 4 3 1 2
1 2 2 2 1 2 2 1 2 1 4 0 0 2
2 1 1 2 2 2 2 1 2 1 4 0 0 2
1 1 1 1 1 2 2 1 1 1 4 0.5 3 2
2 1 1 2 2 2 2 1 2 1 2 7 3 1
2 1 1 2 2 2 2 1 1 1 4 3 2 2
2 1 2 2 2 2 2 1 2 1 4 0.4 3 2
2 2 2 2 1 2 2 1 2 1 4 1 3 2
1 1 1 1 1 2 2 2 1 2 2 3 2 1
2 1 2 2 2 2 2 1 2 1 4 4 3 2
1 2 2 2 2 2 2 1 1 1 2 0.4 2 1
1 1 2 2 1 2 2 1 2 2 2 3 3 1
1 2 2 2 1 1 2 2 2 1 4 0 0 2
2 2 2 2 2 2 2 1 2 2 2 5 3 1
2 1 1 2 2 2 2 1 2 1 4 1 3 2
1 2 2 2 1 1 2 1 2 1 4 0.5 3 2
1 2 2 1 1 1 1 1 2 1 4 1 2 2
1 1 1 2 1 2 2 1 2 2 2 0.5 3 1
1 1 1 2 1 1 1 1 2 2 2 1 2 1
2 1 2 2 1 2 2 1 1 1 2 1 2 1
2 1 2 2 2 2 2 1 2 1 4 0 0 2
1 2 2 2 1 2 2 2 2 2 2 0 0 1
2 2 2 2 2 2 2 1 2 1 2 2 2 1
2 2 2 2 2 2 2 1 1 1 4 0.4 1 2
1 1 1 2 2 2 2 1 2 1 5 8 2 1
1 1 2 2 2 2 2 1 2 1 5 0 0 1
1 1 1 1 1 2 2 1 1 1 5 1 2 1
1 2 2 2 2 2 2 1 1 1 5 2 2 1
1 2 2 1 1 1 2 1 2 1 2 7 2 1
1 2 2 1 1 2 1 1 2 2 2 2 3 1
1 2 2 2 1 2 1 1 1 1 4 1 1 2
1 2 2 1 1 2 2 1 1 1 4 3 3 2
1 2 2 2 1 2 2 1 2 1 5 0 0 1
INFRATENTORIAL CC DAWSON_F Ce BRAIN STEM BG THALAMUS SIZE_LES GADO CERVICAL Cerebral atrophy type F/U MRI after Improvement Atrophy
2 2 2 2 2 2 2 1 2 1 2 3 3 1
1 2 2 2 1 2 2 1 2 2 4 0 0 2
2 2 2 2 1 2 2 1 2 1 2 2 2 1
1 1 1 2 1 2 1 1 2 2 2 3 2 1
2 1 1 2 2 2 2 1 2 1 4 0 0 2
1 1 1 2 1 2 2 1 2 1 2 8 2 1
1 2 2 2 1 1 1 1 2 1 2 1 2 1
1 2 2 2 1 1 2 1 2 1 4 0 0 2
2 2 2 2 2 2 2 1 2 1 2 0 0 1
2 1 2 2 2 2 2 1 2 2 4 1 3 2
1 2 2 2 1 2 2 1 2 1 5 1 2 1
2 1 1 2 2 2 2 1 2 2 2 1 2 1
1 1 1 2 1 1 2 1 1 1 2 3 2 1
2 2 2 2 2 2 2 1 2 2 2 1 3 1
2 2 2 2 2 2 2 1 2 2 4 1 3 2
1 2 2 1 1 2 2 1 2 1 4 4 2 2
1 1 2 2 1 1 1 1 2 2 4 0 0 2
2 1 2 2 1 2 1 1 2 1 2 3 2 1
2 1 1 2 2 2 2 1 2 2 4 1 3 2
1 2 2 2 1 2 2 1 2 2 2 0 0 1
1 2 2 1 1 2 1 1 2 1 5 0 0 1
1 2 2 2 1 2 1 1 2 1 4 0 0 2
2 2 2 2 2 2 2 1 1 1 2 0 0 1
1 1 2 2 2 1 2 1 2 1 4 3 2 2
1 1 1 1 2 2 1 1 2 2 2 3 3 1
1 1 1 1 2 2 2 1 2 1 2 0 0 1
1 1 1 1 2 2 2 1 2 1 4 0 0 2
2 1 1 2 2 2 2 2 2 1 2 1 3 1
1 1 1 1 1 2 2 1 2 1 2 0 0 1
2 1 1 2 2 2 2 1 2 2 4 0 0 2
1 1 1 2 1 2 1 1 2 1 4 0 0 2
1 1 2 2 1 1 1 1 2 1 2 1.6 2 1
2 2 2 2 2 2 2 1 2 1 2 0 0 1
1 1 1 2 1 1 1 1 2 1 2 2 3 1
1 1 1 2 1 2 2 1 2 1 5 0 0 1
1 2 2 1 1 1 1 1 2 1 5 0 0 1
1 1 2 1 1 1 2 1 2 1 4 0.5 1 2
Sl. No M.Predni Pulse MP AZT MMF Mitaxan INF Cyclopho Follow U F/U Durat
1 1 1 2 1 2 2 2 1 9
2 1 1 2 1 1 2 1 1 20
3 1 3 1 2 2 2 2 1 20
4 2 2 2 1 2 2 2 1 3
5 1 2 2 1 2 2 2 1 2
6 1 2 1 2 2 2 2 1 15
7 1 1 2 2 2 2 1 1 6
8 1 1 2 2 2 2 1 1 6
9 1 1 2 1 2 2 2 1 9
10 1 1 2 1 2 1 2 1 1
11 1 1 2 1 2 2 2 1 2
12 1 3 1 2 2 2 2 1 9
13 1 1 2 1 2 1 2 1 7
14 2 1 1 1 2 2 2 1 8
15 2 1 2 2 2 2 1 1 4
16 2 2 1 2 2 2 2 2 0
17 2 1 2 1 2 2 2 1 2
18 1 3 2 1 2 2 2 1 5
19 2 1 2 1 2 2 2 1 9
20 1 2 2 1 2 2 2 1 5
21 1 2 1 1 2 1 2 1 24
22 1 2 1 2 2 2 2 1 14
23 1 1 2 1 2 2 2 1 1
24 1 1 1 2 2 2 1 1 15
25 1 2 1 2 2 2 2 1 12
26 1 1 2 1 2 2 2 1 4
27 1 1 2 1 2 2 2 1 2.5
28 1 1 2 1 2 2 1 1 18
29 1 3 2 1 2 2 2 1 10
30 1 2 1 2 2 2 2 1 12
31 1 1 2 1 2 2 2 1 7
32 1 1 2 1 2 2 2 1 33
33 1 1 1 1 2 2 2 1 9
34 1 2 1 2 2 2 2 1 8
35 1 2 2 1 2 2 2 1 8
36 1 1 2 1 2 2 2 1 8
37 1 3 2 1 2 2 2 1 6
38 1 2 1 2 2 2 2 1 14
39 1 1 2 1 2 2 2 1 3
40 1 2 1 2 2 2 2 1 3
Sl. No M.Predni Pulse MP AZT MMF Mitaxan INF Cyclopho Follow U F/U Durat
41 1 1 2 2 2 2 1 1 22
42 1 1 2 1 2 2 2 1 11
43 1 1 2 1 2 2 2 1 3
44 1 1 2 1 2 2 1 1 5
45 1 1 2 1 2 2 2 1 2
46 1 2 1 1 2 2 2 1 8
47 1 1 2 1 2 2 2 1 9
48 1 1 2 1 2 2 2 1 13
49 1 1 2 1 2 2 2 1 3
50 1 1 2 2 2 1 1 1 12
51 1 1 2 1 2 2 2 1 1
52 1 2 1 2 2 2 2 1 6
53 1 2 1 2 2 2 2 1 10
54 1 1 2 1 2 2 2 1 3
55 1 2 2 1 2 2 2 1 19
56 1 1 2 1 1 2 2 1 3
57 1 1 1 1 2 2 2 1 4
58 1 1 2 1 2 2 2 1 4
59 1 1 2 2 2 2 1 1 5
60 1 1 2 2 2 2 1 1 8
61 1 1 1 1 2 2 2 1 7
62 1 2 1 1 2 1 2 1 16
63 1 1 2 1 2 2 2 1 5
64 1 1 2 1 2 2 2 1 6
65 1 1 2 1 2 2 2 1 2
66 1 1 2 2 2 2 1 1 7
67 1 2 2 2 2 2 2 2 0
68 1 1 2 1 2 2 2 1 25
69 1 1 1 1 2 2 2 1 5
70 1 1 2 1 2 2 2 1 2
71 1 2 1 2 2 2 2 2 0
72 1 1 1 2 2 2 2 1 6
73 1 1 2 1 2 2 2 1 3
74 1 2 2 1 2 2 2 1 6
75 1 1 2 1 2 1 2 1 3
76 1 3 2 1 2 2 1 1 11
77 1 1 2 1 2 2 2 1 3
78 1 1 2 1 2 2 1 1 5
79 1 1 2 1 2 2 2 1 6
80 1 1 2 1 2 2 2 1 4
Sl. No M.Predni Pulse MP AZT MMF Mitaxan INF Cyclopho Follow U F/U Durat
81 1 1 2 1 2 1 2 1 8
82 1 2 2 2 2 2 1 1 4
83 1 1 2 1 2 2 2 2 0
84 1 2 2 2 2 1 2 1 18
85 1 3 2 1 2 2 2 1 9
86 1 2 2 1 2 2 2 1 4
87 1 1 2 1 2 2 1 1 9
88 2 3 2 1 2 2 2 1 9
89 1 2 1 2 2 2 2 1 9
90 1 2 1 2 2 2 2 2 0
91 1 2 2 1 2 2 2 1 13
92 1 1 1 1 2 2 1 1 22
93 1 2 1 2 2 2 2 1 11
94 1 2 1 2 2 2 2 2 0
95 1 2 1 2 2 2 2 2 0
96 2 3 1 1 2 2 2 1 8
97 1 2 1 2 2 2 2 2 0
98 1 2 1 2 2 2 2 2 0
99 1 2 1 2 2 2 2 2 0
100 1 2 2 1 2 2 2 2 0
101 1 2 1 2 2 2 2 1 8
102 1 2 1 2 2 2 2 2 0
103 1 2 2 2 2 2 2 2 0
104 1 1 2 1 2 2 2 1 6
105 1 2 1 2 2 2 2 1 9
106 1 2 1 2 2 2 2 1 7
107 1 2 2 2 2 1 1 1 7
108 1 2 1 2 2 2 2 2 0
109 1 2 1 2 2 2 1 2 0
110 1 2 1 1 2 2 2 1 8
111 2 3 2 1 2 2 2 1 4
112 1 2 1 1 2 2 2 2 0
113 1 2 2 1 2 2 2 2 0
114 1 1 2 1 2 2 2 1 15
115 1 1 1 2 2 2 2 1 6
116 1 3 2 1 2 2 2 2 0
117 1 1 2 1 2 2 1 1 5
118 1 1 2 1 2 2 1 1 3
119 1 3 2 1 2 2 2 2 0
120 1 1 2 2 1 2 2 2 0
Sl. No M.Predni Pulse MP AZT MMF Mitaxan INF Cyclopho Follow U F/U Durat
121 1 2 2 1 2 2 2 1 8
122 1 1 2 1 2 2 2 1 1
123 1 2 1 2 2 1 1 2 0
124 1 3 1 2 2 2 2 2 0
125 1 2 1 2 2 2 2 2 0
126 1 1 1 2 1 2 1 1 19
127 1 2 1 2 2 2 2 2 0
128 1 2 1 2 2 2 2 2 0
129 1 2 1 2 2 2 2 2 0
130 1 2 1 2 2 2 2 2 0
131 2 2 1 2 2 2 2 2 0
132 1 2 1 2 2 2 2 2 0
133 1 2 2 2 2 2 2 2 0
134 1 2 1 2 2 2 2 2 0
135 1 2 1 2 2 2 2 2 0
136 1 2 1 2 2 2 2 2 0
137 1 2 1 2 2 2 2 2 0
138 1 2 1 2 2 2 2 1 17
139 1 2 2 1 2 2 2 2 0
140 1 2 1 2 2 2 2 1 15
141 1 2 1 2 2 2 2 2 0
142 1 2 1 2 2 2 2 2 0
143 1 2 1 2 2 2 2 1 5
144 1 2 1 2 2 2 2 1 13
145 1 2 2 1 2 2 2 2 0
146 1 3 2 1 2 2 2 1 7
147 1 2 1 1 1 2 2 1 8
148 1 2 2 2 2 1 2 1 10
149 1 2 1 2 2 2 2 1 9
150 1 1 2 1 2 2 2 1 4
151 1 1 2 1 2 2 2 2 0
152 1 1 2 1 2 2 2 1 5
153 1 2 1 2 2 1 2 1 17
154 1 1 2 2 2 1 2 2 0
155 1 2 1 2 2 2 2 2 0
156 1 2 1 2 2 2 2 2 0
157 1 2 1 2 2 2 2 2 0
MASTER CHART
Abbreviations
Complete Recovery from 1st episode yes- 1
                                  Incomplete recovery-2
Gender-  Male-1
              Female-2
RR-1, PP-2, SP-3, PR-4
Presentation------    Monophasic-1     poly phasic-2
Male-1 female-2
Acute onset < 7 days- 1, sub acute onset 7 days to 1 month-2, chronic >1 month- 3
Acute-1, subacute-2, chronic-3, Ac+subacute-4, Acute+Subacute+chr-5, 
Subacute+Chronic-6, Acute+chronic-7
Presenting symptom-Visual U/L-1,B/L-2,None-3
Presenting symp Motor-Monoparesis-1, paraparesis-2, quadriparesis-4, hemiparesis-5 
none-6
YES-1      no- 2
Monosymptomatic-1, polysymptomatic-2
CSF protein < 45- 1, 45-90-2, 90-135-3, >135-4
CSF Cells <10-1, 10-25-2, 25-50-3, >50-4
VEP normal -1, U/L abnormal- 2, B/L abnormal-3, not done-4, data not available-5
SSEP median normal-1, abnormal- 2, not done-3, data not available-5
MRI no of lesions- <5-1, 6-10-2, 11-15-3, >15-4
Size of lesions- <3 cm- 1, 3-5 cm- 2, <5 cm-3
MRI improvement-1, worsening- 2, status quo- 3
MRI spinal segments< 3- 1, >3-2
OCB present-1, absent-2, data not available-3
